



Healthcare & Public Health
Sector Coordinating Councils

PUBLIC PRIVATE PARTNERSHIP

1
2

3 **MEDICAL DEVICE AND HEALTH IT**
4 **JOINT SECURITY PLAN**

5 January 2019
6
7
8
9
10
11
12
13
14
15
16
17

18
19 **ABOUT THE HEALTHCARE AND PUBLIC HEALTH**
20 **SECTOR COORDINATING COUNCIL**
21 **JOINT CYBERSECURITY WORKING GROUP**

22
23 The Healthcare and Public Health Sector Coordinating Council (HSCC) is a coalition of private-
24 sector, critical healthcare infrastructure entities organized under Presidential Policy Directive 21
25 and the National Infrastructure Protection Plan to partner with government in the identification
26 and mitigation of strategic threats and vulnerabilities facing the sector’s ability to deliver
27 services and assets to the public. The HSCC Joint Cybersecurity Working Group (JCWG) is a
28 standing working group of the HSCC, composed of more than 200 industry and government
29 organizations working together to develop strategies to address emerging and ongoing
30 cybersecurity challenges to the health sector.

31
32 This Medical Device and Health IT Joint Security Plan is the product of a task group established
33 under the auspices of the HSCC JCWG and composed of medical technology, health IT and
34 health delivery organizations, as well as the FDA, to address a major recommendation of the
35 Health Care Industry Cybersecurity Task Force report from June 2017 calling for a cross-sector
36 strategy to strengthen cybersecurity in medical devices.

37
38 To provide feedback on this tool, please send comments to:
39 **JSPFeedback@HealthSectorCouncil.org**

40
41 For more information on the HSCC, see <https://HealthSectorCouncil.org>.

42	Contents	
43	Acknowledgments	4
44	Executive Summary	7
45	Background	7
46	Purpose and Objectives	8
47	JSP Product Security Framework Overview	9
48	How to Use the JSP	10
49	JSP Product Security Framework Implementation	11
50	Evaluating JSP Progress and Maturity	22
51	Appendix A: Acronyms	28
52	Appendix B: Terminology	29
53	Appendix C: Roles and Responsibilities	33
54	Appendix D: Drafting of the Joint Security Plan	35
55	Appendix E: Example Design Input Requirements for Security	39
56	Appendix F: Example Third-Party Security Agreement	41
57	Appendix G: Example Customer Security Documentation	43
58	Appendix H: Example Organizational Structure	47
59	Appendix I: Example Organizational Training	49
60	Appendix J: Example Security Risk Assessment Methods	51
61	Appendix K: CMMI® for Development	51
62		
63		
64		

65 **I Acknowledgments**

66 The following individuals constitute the membership of the committee established in November
67 2017 who were responsible for development of the Medical Device and Healthcare Information
68 Technology Joint Security Plan.

- 69 • **Task Group Co-Chair**, Kevin McDonald, Director of Clinical Information Security, Mayo
70 Clinic
- 71 • **Task Group Co-Chair**, Rob Suarez, Director of Product Security, Becton, Dickinson &
72 Company
- 73 • **Task Group Co-Chair**, Aftin Ross, Senior Project Manager, Center for Devices and
74 Radiological Health (CDRH) at US Food and Drug Administration
- 75 • Bill Hagestad, Independent Information Security Researcher
- 76 • Colin Morgan, Director, R&D & Product Security, Johnson & Johnson
- 77 • Jim Jacobson, Chief Product and Solution Security Officer, Siemens Healthineers
- 78 • Michael McNeil, Global Product Security & Services Officer, Philips
- 79 • Seth Carmody, Cybersecurity Project Manager, CDRH at US Food and Drug
80 Administration
- 81 • Zach Rothstein, Vice President, Technology and Regulatory Affairs, AdvaMed
- 82 • Ronald Mehring, Chief Information and Security Officer/VP of Technology, Texas Health
83 Resources
- 84 • Hitesh Patadia, Enterprise Architect, Alberta Health Services
- 85 • Kadima Osundwa, Senior Security Analyst, Alberta Health Services
- 86 • Christopher Bennett, Senior Information Security Analyst, Medical University of South
87 Carolina
- 88 • Greg Garcia, Executive Director at Healthcare Sector Coordinating Council
- 89 • Suzanne Schwartz, Associate Director for Science and Strategic Partnerships, CDRH at US
90 Food and Drug Administration
- 91 • Caleb Eggink, Security Solution Leader, Cerner
- 92 • Ali Nakoulima, Lead Technology Architect, Cerner
- 93 • Regina Geierhofer, Regulatory Affairs Manager, Cerner

- 94 • John Travis, Vice President Regulatory Research, Cerner
- 95 • Ray Smith, Lead Software Engineer, Cerner
- 96 • Greg Thole, Senior Regulatory Strategist, Cerner
- 97 • Wil Vargas, Standards Director, Association for the Advancement of Medical
98 Instrumentation
- 99 • Jim Hanson, Information Security Officer, Avera Health
- 100 • Ashley Woyak, Business Information Security Officer, Baxter Healthcare Corporation
- 101 • Ken Hoyme, Director of Product Security, Boston Scientific
- 102 • Michael Maksymow, CIO, Beebe Healthcare
- 103 • Michael Seeberger, Systems Engineer, Boston Scientific
- 104 • Mari Rose Savickis, Vice President of Federal Affairs, CHIME
- 105 • Fernando Blanco, CHRISTUS Health, VP & CISO
- 106 • Aaron Wishon, CISO, Cook Children’s Health Care System
- 107 • Clyde Hewitt, Vice President, Security Strategy / NCHICA Board of Directors,
108 CynergisTek/NCHICA
- 109 • David Klonoff, President, Diabetes Technology Society
- 110 • Charles Stride, Senior VP, CIO/CISO, Holy Redeemer Health System,
- 111 • Paul Connelly, VP/CISO, HCA Healthcare
- 112 • Peter Amadio, Professor of Biomedical Engineering, Mayo Clinic (AEHIS)
- 113 • Greg Garneau, CISO, Marshfield Clinic Health System
- 114 • Lisa Griffin Vincent, VP of Clinical Science, Medical Device Innovation Consortium
- 115 • Elliott Warren, Director of Federal Affairs, Medical Device Manufacturers Association
- 116 • Zack Hornberger, Director of Cybersecurity & Informatics, Medical Imaging Technology
117 Association
- 118 • Matt Russo, Sr. Director of Global Security Office, Medtronic
- 119 • Ari Entin, CIO, Natividad Medical Center (AEHIS)

- 120 • Katie Boyer, Manager of Policy and Advocacy, Nemours Children’s Health System
- 121 • Jon Crosson, Manager of Special Interest Group Services, H-ISAC
- 122 • Nathan Gibson, CIO, Quality Insights (AEHIS)
- 123 • Dr. Sheila Whalen, DNP, RN-BC, Clinical Integration Program Manager, Rush University
124 Medical Center
- 125 • Kevin Scott, Senior Corporate Director of Security and End User Services, Shriners
126 Hospitals for Children
- 127 • Ross Carevic, Director of Business Technology, Vizient
- 128 • Christine Sublett, President &Principal Consultant, Sublett Consulting, LLC
- 129 • Alex Reniers, Cyber Analyst, US Department of Homeland Security

130

131 The HSCC Joint Cybersecurity Working Group TG-1B drafting committee would also like to
132 thank all of the individuals and organizations within the Healthcare Sector Coordinating Council
133 (HSCC) that reviewed and contributed to the plan.

134

135

136 **II Executive Summary**

137 Software-based medical technologies have the potential to positively impact patient care.
138 However, as these products become more connected, product cybersecurity becomes
139 increasingly important as there is the potential for patient harm and disruption of care if products
140 or clinical operations become impacted because of a cybersecurity concern. As product
141 cybersecurity is a shared responsibility, a wide range of healthcare stakeholders under the
142 umbrella of the Healthcare and Public Health Sector Coordinating Council (HSCC), have drafted
143 this Joint Security Plan (JSP) to address cybersecurity challenges. These challenges include but
144 are not limited to transparency and disclosure between vendors and end users, security by design
145 and throughout the product lifecycle, and product end of life. Specifically, the JSP is a total
146 product lifecycle reference guide to developing, deploying and supporting cyber secure
147 technology solutions in the healthcare environment. It includes:

- 148 • Cybersecurity practices in design and development of medical technology products
- 149 • Handling product complaints relating to cybersecurity incidents and vulnerabilities
- 150 • Managing security risk throughout the lifecycle of medical technology
- 151 • Assessing the maturity of a product cybersecurity program

152 The JSP is voluntary and seeks to aid organizations (medical device manufacturers, healthcare
153 information technology (IT) vendors, and healthcare providers) in enhancing their product
154 cybersecurity irrespective of organization size or maturity. It is intended to be globally
155 applicable, inspire organizations to raise the bar for product cybersecurity, and is expected to
156 evolve as product cybersecurity evolves. As such, it is anticipated that there will be future
157 iterations of the JSP and feedback on this initial version is welcome.

158 It is important for medical device manufacturers (MDMs) and health IT vendors, collectively
159 referred to as vendors, to consider the JSP's voluntary framework and its associated plans and
160 templates throughout the lifecycle of medical devices and health IT because doing so is expected
161 to result in better security and thus better products for patients. Security can be difficult to
162 integrate into existing processes for a variety of reasons such as organizations not recognizing its
163 importance, not knowing where to start, and insufficient resources. The components in the JSP
164 framework are used to help create security policy and procedures that align and integrate into
165 existing processes. Our primary ask of organizations is to make a commitment to implementing
166 the JSP as it is expected that patient safety will be positively impacted as a result.

167

168 **III Background**

169 In the *Cybersecurity Act of 2015* (the Act), the United States Congress established the Health
170 Care Industry Cybersecurity (HCIC) Task Force to identify the challenges that the healthcare
171 industry faces when securing and protecting itself against cybersecurity threats. Industry
172 participation in the task force brought to light critical gap areas warranting focus; year-long
173 discussion and analysis culminated in the release of a set of recommendations and action items to
174 address six high-level imperatives.

175 In 2017, a group of medical device manufacturers stepped up to address the recommendations
176 and action items set forth under Imperative 2 of the HCIC Task Force Report: “Increase the
177 security and resilience of medical devices and health IT” by engaging healthcare delivery
178 organizations in a collaborative effort that would produce a Joint Security Plan. This effort was
179 further formalized under the auspices of the Healthcare Sector Coordinating Council’s Joint
180 Cybersecurity Working Group public-private partnership, as the JSP was broadly socialized with
181 healthcare providers, trade associations, security professionals, and government organizations
182 during development and prior to its release. The U.S. Food and Drug Administration, in its role
183 as a key public sector partner, also assisted with the development of the JSP. For additional
184 information on how the JSP was drafted, please see Appendix D. Imperative 2 of the HCIC Task
185 Force Report states:

186 ***Imperative 2. Increase the security and resilience of medical devices and health IT.***
187 *The Health Care and Public Health (HPH) Sector is charged with keeping patients safe*
188 *and that includes protecting patients from physical harm, as well as privacy-related*
189 *harms that may stem from an exploited known cybersecurity vulnerability. If exploited, a*
190 *vulnerability may result in medical device malfunction, disruption of health care services*
191 *(including treatment interventions), inappropriate access to patient information, or*
192 *compromised EHR data integrity. Such outcomes could have a profound impact on*
193 *patient care and safety. Some foundational challenges that will need to be addressed in*
194 *order to enhance the cybersecurity of medical devices and EHRs include legacy*
195 *operating systems, secure development lifecycle, strong authentication, strategic and*
196 *architectural approaches to product deployment, management, and maintenance on*
197 *hospital networks.*
198 *The relatively short lifespan for operating systems and other relevant platforms such as*
199 *commercial off the shelf software is inherently misaligned in health care as medical*
200 *devices and EHRs may be utilized for 10, 15, 20, or more years. This misalignment may*
201 *occur for a variety of reasons. Hospitals operate on thin budgets and cannot replace*
202 *capital equipment like MRIs as quickly as new operating systems are released. Product*
203 *vendors have a product development lifecycle that may take several years and they may*
204 *start development using one operating system and by the time the product comes to*
205 *market, newer operating systems may be available. Creative ways of addressing the*
206 *aforementioned challenge areas may be found by engaging key clinical and cybersecurity*
207 *stakeholders, including software vendors.*

209 The JSP is expected to evolve over time and the HSCC intends to establish a governance model
210 to ensure the baseline strategy is updated based on execution of existing plans or new needs
211 identified by members of the stakeholder community.
212

213 **IV Purpose and Objectives**

214 The HSCC believes that, because medical technology is integral to patient safety and clinical
215 operations, product cybersecurity in medical technology is a shared responsibility among
216 healthcare stakeholders. Moreover, more secure products result in higher quality products
217 which positively impact public health. The JSP is a consensus-based total product lifecycle
218 reference guide for developing, deploying, and supporting cyber secure technology solutions in

219 the health care environment. It is not a regulatory document nor is it a standard. Rather the JSP
220 may be leveraged across an organization’s product portfolio and is intended to be globally
221 applicable. Furthermore, the recommendations provided in the JSP are intended to help
222 organizations of various size and stages of maturity to enhance their product cybersecurity
223 posture by addressing key cybersecurity challenges.

224 This voluntary plan is intentionally forward leaning and seeks to inspire organizations to raise
225 the bar for product cybersecurity. In particular, integrating cybersecurity into an organization
226 necessitates organizational and process changes that come with considerable time and monetary
227 investments. The JSP provides a framework for making these organizational and process related
228 changes.


229 One of the main themes of the JSP is the idea of continuous improvement. We encourage
230 medical device manufacturers, health IT vendors, and healthcare providers to make a
231 commitment to adopting the JSP to aid in developing, deploying, and supporting cyber secure
232 technology solutions in the health care environment. The adoption of the JSP, with the
233 integration into current practices, is expected to provide a safer and more resilient patient care
234 and result in overall improved product quality.
235

236 **V JSP Product Security Framework Overview**

237 The JSP framework establishes that effective cybersecurity is integrated into an organization’s
238 quality system processes and is incorporated throughout the various stages of the
239 commercialization process (from concept to launch). Figure 1 provides a framework for
240 incorporating the JSP into existing quality system processes and throughout commercialization.
241 The core of this framework aligns to traditional quality system concepts. Design controls, risk
242 management, design requirements, testing and post market management can be aligned with
243 multiple software development methodologies (not shown). Documentation of the product
244 security activities/processes in the JSP framework core is encouraged to demonstrate that the
245 framework has been applied consistently and is rigorously followed. Healthcare providers
246 seeking further guidance on the secure operation of medical devices, and other information
247 technology used to run their healthcare operations, may refer to HSCC “[Health Industry
248 Cybersecurity Practices \(HICP\): Managing Threats and Protecting Patients](#)” publication, which
249 stems from the Cybersecurity Information Sharing Act of 2014 (CISA) 405(d) effort. Additional
250 guidance and detail are provided for each product security activity or process identified in the
251 JSP framework in Section VII of this document. Acronyms and term definitions used throughout
252 the JSP may also be found in Appendix A and Appendix B respectively.

253

254



255 **Figure 1. Product Security Framework.** Top row represents product commercialization
 256 phases. Core represents product security activities and processes. Two bottom rows represent
 257 quality system processes
 258

259

260 VI How to Use the JSP

261 For the successful use of the JSP, an initial step is to be able to define the governance process as
 262 it relates to organizational roles and responsibilities, and the needs for personnel training.

263 Governance which may include strategic decisions, establishing milestones, and tracking of
 264 maturity against the framework is executed by designated leaders in a vendor's organization.
 265 Framework adoption should be driven by mapping each of the framework cybersecurity
 266 activities and processes into existing processes and minimizing the creation of separate or
 267 redundant processes. Again, the goal of implementing the JSP is to generate higher quality
 268 products that positively impact patient safety.

269 In addition to organizational leadership, various members of the organization have a shared
 270 responsibility for product security and thus benefit from the implementation of the JSP. For
 271 example, a vendor may share its evaluation of maturity against the JSP with customers. The
 272 vendor may also share this information with the HSCC with the intent of informing future
 273 iterations of the JSP. Additional granularity regarding stakeholder roles and responsibilities as
 274 well as potential organizational structures for implementing security are found in Appendix C
 275 and Appendix H respectively.

276 Organizations adopting this framework should consider providing existing personnel with
 277 necessary training to achieve focused incorporation of cybersecurity expertise (see Appendix I

278 for additional granularity regarding on organizational training). Maintaining functional
279 competency can best be achieved by establishing a routine training regimen or periodic re-
280 assessment of need.

281 282 **VII JSP Product Security Framework Implementation**

283 This section expands and articulates on security activities and processes in the JSP framework
284 (see Figure 1) in the context of where they align with traditional quality systems processes, and
285 cross references appendices with applicable examples and templates. The goal in adopting the
286 JSP is to integrate the security activities and processes in the JSP framework into existing
287 processes where applicable. For additional information regarding the authoritative sources that
288 were used to draft the content that follows, please see Appendix D.

289 **A. Risk Management**

290 Product security risk assessment is an integral component of overall product risk management.
291 There are specific considerations necessary for ensuring cybersecurity risks identified during
292 design, development, or post launch complaint handling are properly analyzed, evaluated, and
293 documented. This section describes risk management from product concept through product
294 launch.

295 **i. Risk Register**

296 A risk register, also referred to as a risk log, may be standalone or multiple repositories,
297 which can be used to report on efforts across the framework activities, track remediation,
298 and map new known vulnerabilities or potential risks. For vendors, the risk register will
299 be populated from product portfolio management and information from the cybersecurity
300 management plans as described below. Customers also benefit from maintaining a risk
301 register based on information from customer security documentation (see Section VII,
302 Design Control, subsection vi(b) for a description of customer security documentation)
303 and vulnerability disclosures from vendors.

304 **ii. Cybersecurity Management Plan**

305 Beginning at the concept phase, a plan is created to establish how cybersecurity will be
306 managed throughout the product lifecycle of the vendor's product. This plan is
307 maintained throughout the product lifecycle and includes:

- 308 • Reports for product security risk assessment, penetration testing, static code
309 analysis, and vulnerability scanning
- 310 • Documentation of secure coding standards and system hardening standards
311 applied during development and at installation
- 312 • Plans for incident management, vulnerability management, and patch
313 management
- 314 • Documentation of service, remote support, and decommissioning procedures
315 which may also be reflected in service contracts
- 316 • Customer security documentation that is ready for customer distribution
- 317 • Documentation of exceptions (see Section VII, Compliant Handling and
318 Reporting, subsection v for a description of exceptions)

319 This management plan should be cross-functionally reviewed and approved by business
320 leadership in a vendor’s organization. Components of this plan necessary for operation
321 and management of product security are provided to customers by inclusion in customer
322 security documentation, user manuals, and reflected in contractual agreements between
323 the vendor and customer.

324 **iii. Product Security Risk Assessment**

325 **Product Inventory**


326 Document and maintain a comprehensive list of all software enabled products, product
327 versions, solutions, and services commercially available, in support or in development, in
328 order to track cybersecurity risks.

329 Security risk assessment may be performed as part of or separately from other types of
330 risk assessment, including those described in ISO 14971. The objective of risk
331 assessment for known vulnerabilities or potential cybersecurity risks is to determine the
332 comprehensive impact, for example, to clinical safety, business operations, intellectual
333 property, patient privacy, contractual requirements, regulation, and law. The risk
334 assessment will also enable the risks and vulnerabilities to be prioritized for response.
335 Figure 2 is an example of: the sources from which a known vulnerability may be
336 identified; the analysis categories used to score the vulnerability; and the output of the
337 risk assessment. Risk assessments should reflect the target operational environment and
338 use case of the product.

339 Known common vulnerabilities and exposures (CVEs) identified in design and
340 development or during complaint investigation of a launched product are analyzed and
341 evaluated using a consistent vulnerability scoring methodology. One methodology that
342 may be leveraged is the common vulnerability scoring system (CVSS). If CVSS is used,
343 the latest version available should be used at the time of risk assessment to derive the
344 level of cybersecurity risk and information that may be further used in preliminary hazard
345 analysis (PHA), failure mode and effects analysis (FMEA), or other risk assessment tools
346 not specific to cybersecurity, as indicated in Figure 3. Utilizing the most recent version
347 of CVSS can help in this analysis and avoid challenges with determining exploitability
348 for security risks. For many vulnerabilities, CVSS scoring may already be provided based
349 on original equipment manufacturer (OEM) or industry evaluation, but it is recommended
350 that CVSS is calculated specific to the product’s implementation with consideration for
351 worst case scenarios where implementation is not strictly controlled (See Appendix J for
352 more information on a draft CVSS rubric for the healthcare context which may aid in this
353 assessment).

354

355




356
 357 **Figure 2. Risk Assessment Sources.** Assessing risk from different sources and generating
 358 severity scoring that may be used in safety-related risk assessment.

359
 360 As it relates to Figure 2 above:

- 361 • None to low risk means negligible or no impact to confidentiality, integrity, or
- 362 • Medium to high risk means potential known vulnerabilities that may result in
- 363 • Critical risk introduces potential for injury or harm to patients or users of products

372



373
374 **Figure 3. Risk Assessment Mapping.** Illustration of how a safety-related risk management
375 process maps to a security-related issue for medical technology

376 **iv. Additional Risk Management Areas**

377 **Supply Chain**

378 Secure, according to a vendor information security policy, development and
379 manufacturing environments such that additional security risk is addressed prior to
380 deployment of a product to a customer. These measures should include malware
381 protection measures, file system integrity checking, and access control for intellectual
382 property during the supply chain process.

383 **Third-Party Entities**

384 It is important that external entities involved in the product lifecycle of a medical device
385 or healthcare information technology ensure applicable components described in the JSP
386 framework (Figure 1) can be achieved. Furthermore, by undergoing routine assessment
387 against the applicable components of this framework, third-party entities demonstrate
388 their commitment to further bolstering the state of medical device and health IT security.
389 Additional granularity is provided in an example of a third-party security agreement in
390 Appendix F.

391 **B. Design Control**

392 Design controls consist of policies and procedures that ensure that product design inputs are met
393 so that correct requirements can be developed. For cybersecurity, organizations apply applicable
394 standards and testing to software code during product development as well as during each
395 software release. These design control principles also apply to components provided by third-
396 parties that are used in finished products. The section that follows describes components of the

397 JSP security framework relevant to design control from product concept through product
398 qualification.

399 **i. Design Input Requirements for Security**

400 As a subset of design input requirements, establish high-level security requirements based
401 on: authoritative sources for security standards and best practices; a vendor's own
402 security requirements when they verifiably exceed existing standards; regulatory
403 requirements for security of technology or medical technology specifically, and customer
404 feedback relating to security. These requirements should be assessed for applicability to a
405 product during the design and development processes (Figure 1). Additional specifics
406 regarding some of these requirements are found in Appendix E. It is expected that
407 additional information regarding cybersecurity vulnerabilities may be obtained once the
408 product is launched. As a result, it is important to incorporate known cybersecurity
409 vulnerabilities and relevant compensating controls into the design control process (i.e.
410 into design control policy and procedures).

411 **ii. System Requirements, System Hardening Standards, and Vulnerability**
412 **Scanning**

- 413 • Identify, apply and maintain system hardening standards provided by a third-party
414 component vendor or an authoritative source for securely configuring all products
415 and components used in a vendor product. See Appendix D for examples of
416 authoritative sources for standards and testing.
- 417 • Perform vulnerability scanning periodically throughout product development and
418 conduct automated testing to ensure secure system configuration and patching.

419 **iii. Software Requirements, Secure Coding Standards, and Code Analysis**

- 420 • Apply secure coding standards during the development of software that outline
421 secure coding practices generic to any programming language, and language-
422 specific secure coding standards specific to a programming language.
- 423 • Perform static and dynamic code analysis periodically throughout product
424 development testing and integrate automated solutions into development tools to
425 ensure secure coding standards are followed.

426 **iv. Patch Management Requirements**

427 Routinely identify, apply and maintain system-patching throughout the product
428 development process for products and components, including those provided by third-
429 parties. Consider remediation planning within a reasonable timeframe - including an
430 upgrade of the products and components - if patches are no longer supported by their
431 third-party vendor. The deployment and application of patches will have a defined time
432 of disruption to system operation and minimal impact on availability for patient care. See
433 Section VII, Complaint Handling and Reporting, subsection vi for additional granularity
434 on vulnerability and patch management once the product is launched.

435 **v. Security Testing**

- 436 • Conduct robustness testing during unit and integration testing of proprietary
437 software in development; test interfaces such as user interfaces, network
438 protocols, and file inputs for ability to withstand and handle potentially malicious

439 input, as well as denial of service attacks and events; and apply standard IT
440 practices such as vulnerability scanning.
441 • Conduct penetration testing. It is paramount that an independent entity trained
442 and/or certified in cybersecurity verifies cybersecurity testing performed and
443 security controls implemented during design control, as well as in each software
444 release near or at completion of risk remediation. Additionally, they may apply
445 custom cybersecurity testing methodologies based on threat modeling to ensure
446 comprehensive use case coverage. Based on product complexity, connectivity,
447 and integration with customer environments and reliance on customer security
448 controls, a penetration test is recommended on the product in its deployed
449 configuration prior to customer use. Documentation by the vendor of penetration
450 testing reports is critical to include in product design documentation and the
451 cybersecurity management plan; include unmitigated findings in customer
452 security documentation.

453 **vi. Customer Security Requirements**

454 **a) Service and Support Access**

455 When remotely or locally accessing customer systems, it is critical that a vendor
456 maintain permissible security and privacy controls and adhere to customer
457 information security policies. Support tools and processes should be monitored
458 for vulnerabilities and insecure practices. The vendor is responsible for providing
459 customer security documentation which comprehensively describes the control
460 measures implemented. In particular, vendor service and support personnel in
461 collaboration with customers are responsible for:

- 462 • Obtaining consent from the customer prior to accessing customer
463 environments in addition to uniquely identifying service and support
464 personnel upon authentication and authorization to a system. Also, document
465 processes for how and when local and remote access is performed for service
466 and support.
- 467 • Avoiding inclusion of any credentials in product information documentation
468 such as service manuals, which may allow unauthorized access to the product.
469 Default passwords or credentials may be documented when instructions are
470 provided to make those credentials unique.
- 471 • Ensuring system cybersecurity controls are always returned to intended
472 configuration prior to completing any vendor service and support visit.

473
474 In addition:

- 475 • Credentials and passwords should be unique, changed on a regular basis and
476 immediately removed or changed following any service personnel
477 termination.
- 478 • Remote access should be done using some type of multi-factor authentication.
- 479 • Customer data, including patient data, may never leave the site without
480 written consent and approval from the customer. Data should be de-identified
481 when possible and a clear communication of use of the data must be provided.
- 482 • Any use of removable media should be approved by customers and customer
483 information security policies should be adhered to before utilization.

- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- Decommissioning or transfer of products and components from a customer facility, or removal for refurbishment, requires any sensitive information and data to be destroyed or transferred with reasonable and appropriate safeguards with the customer’s written authorization.
 - Customers may accept responsibility to destroy sensitive information and data from any product if they wish to do so. Clearly document and follow any federal and local regulatory or legal procedures for transfers of this data.
 - Service may determine approved methods for managing sensitive information and data. In accordance with customer data retention requirements, the destruction of this data must be clearly documented and follow any local regulatory or legal procedures.

496 **b) Customer Security Documentation**

497 For any commercialized product, it is critical that the vendor develop and

498 maintain documentation which describes all pertinent security information related

499 to the product. Furthermore, customer security documentation needs to be

500 updated when significant changes occur in existing or new product versions. This

501 documentation is prepared for external distribution and consumption by

502 customers. Customers, in turn, are responsible for processing vendor-provided

503 customer security documentation to complete questionnaires, agreements, and/or

504 risk assessments during product procurement phases and incorporating results into

505 a risk management platform as well as an asset management platform for ongoing

506 management.

507 Customer security documentation provided by vendors includes:

- 508
- 509
- 510
- 511
- 512
- 513
- 514
- 515
- 516
- 517
- 518
- 519
- 520
- 521
- 522
- 523
- 524
- All components provided or required for use, also known as a bill of materials, using the common platform enumeration convention and major version number. This would include components such as software (commercial and open source) and firmware required for device operation
 - Description of secure configuration
 - Data flow diagrams that capture items flowing in and out of the device, open network ports and active services, as well as any requirements for network connectivity
 - Remote access methods and tools, if used
 - Access control design including privileged access controls and vendor maintenance and/or service accounts
 - Comprehensive description of the control measures implemented
 - Patch management plan developed by the vendor that identifies any customer responsibility as part of the plan
 - Required cybersecurity controls including malware protection that supported the vendor risk assessment
 - Logging and audit capabilities to support customer security operations

- 525 • Assumptions and requirements at installation and in use to maintain security
 - 526 • Summary of known security risks and considerations, including unmitigated
 - 527 findings from penetration testing
 - 528 • Contact information for the vendor to report incidents, vulnerabilities, or for
 - 529 general inquiries regarding security
- 530 For context regarding what may be included in customer security documentation
- 531 and what it might look like, see Appendix G.

532 **C. Complaint Handling and Reporting**

533 Gathering feedback on the cybersecurity performance of their products post product launch is

534 important for vendors, and complaints are a mechanism for obtaining this feedback. The section

535 that follows provides insight into the types of information vendors may receive and actions they

536 may take as a result.

537 **i. Customer Complaint Escalation**

538 Customer complaint evaluation or investigation by the vendor includes steps to determine

539 if there is a product-related cybersecurity vulnerability or incident. A cross-functional

540 team may be assembled to ensure a coordinated investigation and appropriate response.

541 Specifically, the investigation includes close coordination with the affected customers

542 and appropriate parties. Ensure effective escalation and triage by having adequate

543 procedures and classification for potential cybersecurity issues for handling by service

544 and support. Customers and vendors should perform timely information sharing during an

545 investigation to support rapid response.

546 If the customer product complaint is associated with protected health information or

547 personally identifiable information, then privacy considerations must be accounted for

548 (e.g. privacy notifications, breach investigation) and other potentially affected customers

549 must be notified. The vendor should provide information needed for proper incident

550 response to enable successful breach determinations.

551 If the complaint is associated with vendor managed or owned assets but not a vendor

552 product, such as a service laptop or removable media, then upon receiving the complaint

553 the vendor will inform its information security organization. Depending on the type of

554 incident, notification of privacy or compliance officers may be needed as well. Additional

555 responses may also be needed that include customer or regulatory notification.

556 Risk assessment and remediation planning is an integral part of the complaint

557 investigation. As a part of this assessment, product cybersecurity risks are documented in

558 service and support complaint handling systems in addition to risk management files.

559 Remediation may include advised compensating controls and fixes as appropriate.

560 **ii. Reporting Considerations**

561 In the interest of strengthening cybersecurity within the medical technology ecosystem, it

562 is essential for vendors to communicate cybersecurity vulnerabilities to appropriate

563 stakeholders. In addition to vendor customers, these stakeholders include Cyber

564 Emergency Response Teams (CERTs) and groups that share medical technology

565 vulnerability and threat information (e.g. information sharing and analysis organizations).


566 Vendors should also be aware of any additional reporting and remediation requirements
 567 imposed by regulators in the jurisdictions in which they operate (e.g. FDA guidance on
 568 Postmarket Management of Cybersecurity in Medical Devices for medical device
 569 manufacturers marketing product in the US), as these vulnerabilities may pose patient
 570 safety concerns.

571 **iii. Security Incident Management, Response and Communication**

572 Provide timely responses and communications to all stakeholders impacted by
 573 vulnerabilities and incidents for commercialized products as described below.

- 574 • Manage internally reported issues within 30 days of initial discovery and the
 575 designated cross-functional team provides an update of the issue status to internal
 576 stakeholders and governance every 60 days thereafter until closure.
- 577 • Produce targeted customer bulletins or notifications and post to a public webpage
 578 or deliver via other available mechanisms to customers within 30 days of initial
 579 discovery for customer and third-party reported issues. Evaluate related customer
 580 security documentation to determine if updates are indicated; if deemed
 581 necessary, proceed to update. Provide status updates to customers and third-
 582 parties reporting vulnerabilities and incidents with a routine cadence established
 583 by the cross-functional team while complaint handling investigation is in
 584 progress. Achieving the aforementioned timing for bulletins or notifications by
 585 the vendor during incidents may be dependent on timely and accurate
 586 communication with customers.
- 587 • Coordinate vulnerability disclosures with a Cyber Emergency Response Team
 588 (CERT) and Information Sharing and Analysis Organization (ISAO) recognized
 589 by the FDA. For an overview of vulnerability disclosure terms, definitions,
 590 concepts, guidelines, and benefits please see the international standard and white
 591 paper referenced under “Security Incident Response and Communication” in
 592 Appendix D. Though out of scope for this document, other reporting such as that
 593 required by federal (e.g. the Health Insurance Portability and Accountability Act
 594 (HIPAA)) and state laws, regulatory compliance etc. may be needed. Figure 4
 595 below is an example of a coordinated vulnerability disclosure process.

596



597 **Figure 4. Example coordinated vulnerability disclosure process.** Organizations obtain
 598 vulnerability information by monitoring various sources. Subsequently a potential vulnerability
 599 is identified, assessed, verified, remediated, and communicated as appropriate.
 600

601 **iv. Remediation Planning**

602 Throughout design and development, a product security risk assessment is necessary to
603 determine the level of risk and subsequent actions for security requirements including
604 remediation planning. Below is an example of how low, medium and high risks can be
605 managed.

- 606 • Low risk can be addressed or accepted as is and documented as an exception (see
607 following section to learn more about exceptions)
- 608 • Medium to high and critical risk can be addressed as requirements for design
609 input and mitigated accordingly
- 610 • Routine vulnerability and patch management may be addressed continuously

611 For commercialized products, security risk assessment and remediation planning is
612 performed as part of a post market management (post-launch) process.

- 613 • Low risks may be addressed separately in a reasonable amount of time, but at
614 minimum during the next product or software update
- 615 • Recommendations for medium to high and critical risks, which may align with
616 uncontrolled risks per FDA’s guidance Postmarket Management of Cybersecurity
617 in Medical Devices, include communicating with the customer and user
618 community about the vulnerability, identifying the devices which could
619 potentially be impacted and providing interim control measures to mitigate risk as
620 well as a remediation plan within 30 days of learning of the vulnerability. Patches
621 must be available with at least one of the deployment methods promptly and
622 within a maximum of 60 days after learning of the vulnerability. As soon as
623 possible but no later than 60 days after learning of the vulnerability, the
624 manufacturer fixes the vulnerability, validates the change, and distributes the
625 deployable fix to its customers and user community such that the residual risk is
626 brought down to an acceptable level.
- 627 • Risks which have resulted in an incident where unauthorized disclosure of PHI or
628 PII will require data breach investigation and potential notification to customers
629 in accordance with local laws and regulation. Other sensitive information and
630 data such as intellectual property will require data breach investigation and
631 potential notification to stakeholders.

632 Corrective and preventive action plans (CAPA) are established in compliance
633 with vendor CAPA policy/procedure in order to evaluate the need to correct
634 existing or potential quality issues that impact the security of products and to
635 develop actions to prevent their occurrence or recurrence.

636 **v. Exceptions**

637 An exception is an instance when a cybersecurity risk is identified (both pre- and post-
638 launch of the product) and the vendor determines that no action is needed. As is
639 appropriate in all cases, it is important for the manufacturer to document the risk in the
640 product’s design history file and/or risk management files. For risks documented as
641 exceptions that require compensating controls to reduce the risk to none-to-low risk, a
642 description of the risk and the compensating controls, including associated procedures,
643 should be provided in customer security documentation for the product.

644 **vi. Vulnerability Management and Patch Management**

645 Prior to commercialization, a vendor establishes a cybersecurity management plan to
646 identify, evaluate, and respond to any cybersecurity incident or vulnerability including
647 known and zero-day vulnerabilities. The plan would not be complete without addressing
648 routine patching throughout the product lifecycle. Standardizing a pre-determined
649 frequency for patches and updates is recommended, with a quarterly frequency at
650 minimum. Publishing and coordinating patches in a timely manner so as to mitigate
651 medium to high risk vulnerabilities is of prime importance to any vulnerability and patch
652 management program. Critical elements of a vulnerability and patch management plan
653 include the ability to:

- 654
- 655 • Continuously monitor, track, and plan for cybersecurity incidents, vulnerabilities,
656 upstream patches, and end of support dates from predefined sources based on
657 inventory of firmware, software, communication modules, etc. Products and
658 components (including those contracted components provided by third-party
659 entities) may also be a source of vulnerabilities and should similarly be subject to
660 monitoring
- 661 • Determine the level of risk and subsequent actions necessary to mitigate
662 cybersecurity risks by using product risk assessment, remediation planning and
663 product security risk assessment. In particular, document cybersecurity risks in
664 defect, bug, or issue tracking systems or product backlog, in addition to design
665 history files and/or risk management files
- 666 • Validate the remediation and successful patching of vulnerabilities, including
667 impact to performance and clinical use
- 668 • Perform proper version controlling to ensure patches can be identified once
669 deployed on products
- 670 • Identify capabilities necessary for customers and vendors to determine if a
671 security incident has occurred from any exploited vulnerability
- 672 • Deploy remediation, including routine and emergency software patches, by
673 implementing at least one of the following secured methods that are then
674 documented by both vendor and customer:
 - 675 ▪ Remote Update: Patches applied via secure authorized remote service and
676 support platforms provided by the vendor
 - 677 ▪ Customer Administered: Validated patches will be made available for
678 customer retrieval and installation from a designated source including
679 direct download from the third-party that provides the product or
680 component
 - 681 ▪ Service Visit: Local service administered cybersecurity patches. Note that
682 this method is less optimal due to the time required to deploy local service
683 personnel to customer facilities. However, it has utility in cases where
684 faulty patching has foreseeable and serious safety risk and local service
685 personnel may be required for resolution
 - 686 ▪ Ad-hoc Patching: Customers may accept engineering and technical risk
687 for all other deployment mechanisms and/or application of cybersecurity
688 patches not validated by the vendor. Note that this method is not advised
689 due to the lack of validation by the vendor and potential impact to system
690 performance or patient safety

- 691
- 692
- 693
- 694
- 695
- 696
- 697
- 698
- 699
- 700
- 701
- 702
- Make customers aware of the availability of cybersecurity patches and upgrades for products through a public webpage and/or direct customer notification (e.g., email followed by letter).
 - For vendor-managed remote updates and service visits, routine reporting to customers of failures to patch products in the field is necessary, including products and components provided by third-party entities that are no longer supported by their vendor
 - It is essential that customers establish processes and/or technical means for routinely monitoring the designated communication channels predefined by the vendor for new information or changes regarding patches

vii. End of Life/ End of Support and Decommissioning

703 The cybersecurity management plan incorporates consideration for appropriate actions

704 for the vendor and its customers when security for the product can no longer be supported

705 or when the vendor discontinues support and maintenance of the product.

- 706
- 707
- 708
- 709
- 710
- 711
- 712
- 713
- 714
- 715
- 716
- 717
- 718
- 719
- 720
- 721
- 722
- 723
- 724
- 725
- 726
- 727
- Consideration for end of support includes when third-party products and components are no longer supported by their manufacturer or developer and when known common vulnerabilities and exposures are identified but not remediated by the third-party component manufacturer or developer. Provide anticipated end of life and end of support dates to customers as part of customer security documentation.
 - For commercialized products that will receive an end of life or end of support date for the first time, a reasonable amount of advanced notification is recommended so that customers can take any necessary action including removal of network connectivity, transition to a supported product, and implementation of compensating controls provided by the vendor as part of end of life and end of support. At a minimum, 3 years is considered a reasonable amount of time between communicating and making effective end of life or end of support.
 - Customers should be aware of the end of life and end of support dates for systems in their inventory and make risk-based decisions on their replacement or continued use. If intending to replace, organizations can develop replacement/upgrade plans for each system. If the decision is continued use beyond the end of life and end of support dates, the customer is advised to perform a risk assessment to determine risk reduction strategies it can perform independently, which may include network segmentation, isolation, system hardening, or other defense-in-depth strategies.

VIII Evaluating JSP Progress and Maturity

A. Evaluating Progress

730 An organization involved in the design, development, production, deployment, service, and

731 support of medical device and healthcare information technology may establish means for

732 achieving each of the applicable plan components with target dates and periodically assessing

733 progress and maturity against the JSP. The table below is an example of a JSP maturity

734 assessment. Once the framework is understood, it is recommended that an initial assessment is

735 completed and the follow-ups scheduled and executed. Note that other maturity assessments may
 736 be of value and additional information on the CMMI maturity assessment is found in Appendix
 737 K.

738

Plan Component	Description	Current Maturity	Target Maturity	Milestones
----------------	-------------	------------------	-----------------	------------

Organization

Structure	Does the organization have a Chief Product Security Officer? Does the organization have a product security function? Are the product security functions roles & responsibilities clearly defined? Is the product security function staffed appropriately?	[1-5]	[1-5]	[YYYY/MM]
------------------	--	-------	-------	-----------

Governance	Are there existing policies and/or procedures that cover product security? Has organizational leadership approved of the product security policy and procedures? Is the organization audited against product security policies/procedures? How frequently? Are product security metrics briefed to leadership such as Chief Quality Officer, Chief Medical Safety Officer, R&D leadership, etc.? If so, how frequently?			
-------------------	--	--	--	--

739

Risk Management

Risk Register	Has an inventory of products been created for	[1-5]	[1-5]	[YYYY/MM]
----------------------	---	-------	-------	-----------

Risk Assessment	<p>commercialized products and products in development?</p> <p>Are security risks tracked in R&D defect tracking systems, design history or risk management files?</p> <p>Are security risks tracked in service complaint handling systems or risk management files?</p>			
	<p>Is there an established method used for security risk assessment?</p> <p>Have policies and procedures been updated to incorporate security risk assessment and triage to other types of risk assessment?</p>			
Supply Chain	<p>Are development and manufacturing environments assessed and managed for adherence to information security policy?</p>	[1-5]	[1-5]	[YYYY/MM]
Third-Party Entities	<p>Have third-parties been assessed against the components of this framework?</p> <p>Are third-parties routinely assessed for security?</p> <p>Does the organization have security requirements in the contract language for suppliers and third-parties?</p>			
Exceptions	<p>Are exceptions to framework components documented in design history and/or risk management files?</p> <p>Are compensating controls associated with exceptions provided in customer security documentation?</p>			

Design Control				
Design Input Security Requirements	Are cybersecurity requirements incorporated in design input for products in development?	[1-5]	[1-5]	[YYYY/MM]
Standards and Testing	<p>Are system hardening standards, system patching, and vulnerability scanning incorporated in product development practices?</p> <p>Are secure coding standards and code analysis incorporated in product development practices?</p> <p>Is security testing such as penetration testing performed by trained cybersecurity professionals during design control?</p> <p>Is robustness testing performed during product development?</p>			
Vulnerability Management & Patch Management	<p>Have processes been instituted to monitor, identify, assess, remediate, and validate security patches for product software and third-party components?</p> <p>Are validated patches deployed using an established method?</p> <p>Can reports be generated to show patching failures?</p> <p>Is there a public webpage where customers can go to identify new patches?</p>			
Customer Requirements	Do service and support personnel have procedures for requesting access to customer			

Cybersecurity Management Plan	<p>systems and restoring security measures?</p> <p>Are controls in place for service personnel to uniquely authenticate to customer systems?</p> <p>Is there established policy and procedures around the use of removable media with products and handling of customer data?</p>			
	<p>Are plans in place to maintain security throughout the lifecycle of a product?</p> <p>Do products have anticipated end of life and/or end of support dates established with consideration to supporting third-party products and components?</p>			
Complaint Handling				
Customer Complaint Escalation	<p>Do escalation procedures define cybersecurity signals?</p> <p>Are customer reported cybersecurity issues documented in complaint handling systems?</p> <p>Are processes in place to ensure review of reported complaints related to cybersecurity?</p>	[1-5]	[1-5]	[YYYY/MM]
	<p>Have processes been established to notify a CERT, ISAO, and/or regulator as appropriate of reported cybersecurity issues?</p>			
	Reporting Considerations			
Security Incident Management, Response and Communication	<p>Are internal teams engaged within 30 days of a reported security incident and updated every 60 days thereafter?</p>			

Remediation Planning	Are the incident response processes regularly practiced?			
	Is there a public webpage where bulletins or advisories relating to vulnerabilities or incidents can be posted?			
	Are there clearly defined criteria for remediation of security risk for products in development?			
	Are there clearly defined criteria for remediation of security risk for commercialized product?			
	Are medium to critical vulnerabilities communicated to customers within 30 days?			
	Are medium to critical vulnerabilities remediated within 60 days?			

740 **B. Maturity Levels**

741 The following levels are used to describe the state of maturity for individual components of the
742 Joint Security Plan. In order to move to a higher maturity level, all the elements of previous
743 levels should be satisfied.

744 **Level 1: Initial**

745 One or multiple framework components have been presented to internal stakeholders
746 and plans have been drafted, but there is no proven or formalized process nor people
747 responsible.

748 **Level 2: Managed**

749 Framework components have been planned and execution is underway. The
750 established plans ensure framework components are performed, measured, and
751 controlled with routine visibility provided to management.

752 **Level 3: Defined**

753 All of the framework components have been achieved. Formal policies and
754 procedures have been established as well as incorporated in quality management
755 systems. Internal stakeholders have been provided clear description of activities and
756 are provided training. Deliverables for the framework component are well
757 documented and routinely reviewed among internal stakeholders.

758 **Level 4: Quantitatively Managed**

759 All aspects of a framework component are achieved and various performance metrics
760 are collected to determine areas of improvement. The following are performance
761 metrics that may be considered:

- 762 • Number of reported security complaints
 - 763 ▪ Average response time to customers
 - 764 ▪ Average time to closure for security complaints
 - 765 ▪ Average time to customer communication
- 766 • Number of cybersecurity defects out of design control
 - 767 ▪ Average time to remediation
- 768 • Percentage of patches successfully applied remotely to deployed product
- 769 • Percentage of patches successfully applied by customers to deployed product
- 770 • Percentage of patches successfully applied by service to deployed product
- 771

772 **Level 5: Optimizing**

773 Metrics collected on a framework component are routinely reviewed and process
774 improvement plans are established. Quantitative process improvement objectives are
775 established and continuously revised to reflect changes to industry standards and the
776 JSP. Review of quantitative analysis produces predictable results. Process variation
777 across multiple products is understood and when variation produces under-
778 performance it is addressed through the creation of process improvement plans with
779 cross-functional ownership. The process of continuous improvement is intrinsic to all
780 those involved in the design, development, production, deployment, service, and
781 support of medical device and healthcare information technology.
782

783 **Appendix A: Acronyms**

784 This appendix section provides an overview of the acronyms used in this document.

785	C-I-A	Confidentiality Integrity Availability
786	CISO	Chief Information Security Officer
787	DHS	U.S. Department of Homeland Security
788	EHR	Electronic Health Record
789	EU	European Union
790	FDA	U.S. Food and Drug Administration
791	GDPR	General Data Protection Regulation
792	HDO	Healthcare Delivery Organization
793	HCIC Task Force	Health Care Industry Cybersecurity Task Force
794	HHS	U.S. Department of Health and Human Services
795	HIMSS	Healthcare Information and Management Systems Society

796	HIPAA	Health Insurance Portability and Accountability Act
797	HPH	Healthcare and Public Health
798	IT	Information Technology
799	ISAO	Information Sharing and Analysis Organization
800	ISAC	Information Sharing and Analysis Center
801	MDM	Medical Device Manufacturer
802	NIST SP	National Institute of Standards and Technology Special Publication
803	NIS	Network and Information Systems Directive (EU) 2016/1148)
804	H-ISAC	Health Information Sharing and Analysis Center
805	NCCoE	National Cybersecurity Center of Excellence
806	NSA	National Security Agency
807	PHI	Protected Health Information
808	PII	Personally Identifiable Information
809	R&D	Research and Development
810	SDL	Security Development Lifecycle
811	SDLC	Software Development Life Cycle
812	U.S.	United States
813		

814 **Appendix B: Terminology**

815 Various cybersecurity and healthcare centric terms are used throughout this document. This
816 appendix section provides an overview of what is meant by some of these key terms. Note that
817 some of these terminologies and definitions were derived from authoritative sources listed in
818 Appendix D which describes the drafting of the Joint Security Plan.

819 **Code Analysis:** Source code analysis is the automated testing of a program’s source code with
820 the purpose of finding faults and fixing them before the software is sold or distributed.

821 **Common Platform Enumeration (CPE):** An industry standard structured naming scheme for
822 information technology systems, software, and packages.

823 **Common Vulnerability Exposure (CVE):** CVE is a list of information security vulnerabilities
824 and exposures that aims to provide common names for publicly known problems

825 **Common Vulnerability Scoring System (CVSS):** A security industry standard for prioritizing
826 the severity of security issues.

827 **Compensating Controls:** Alternative security controls employed by organizations in lieu of
828 specific controls. These are controls that provide equivalent or comparable protection for
829 organizational information systems and the information processed, stored, or transmitted by
830 those systems.

831 **Complaint Handling:** Process for receiving, reviewing, and evaluating complaints.

832 **Coordinated Vulnerability Disclosure:** The process of gathering information from
833 vulnerability finders, coordinating the sharing of that information between relevant stakeholders,
834 and disclosing the existence of software vulnerabilities and their mitigations to various
835 stakeholders, including the public

836 **Controlled Risk:** Controlled risk is present when there is sufficiently low (acceptable) residual
837 risk of patient harm due to a device’s particular cybersecurity vulnerability.

838 **Critical Functions:** Any product functionality which impacts the clinical safety or significantly
839 disrupts the business operations of Customers.

840 **Customers:** Includes healthcare providers and patients.

841 **Customer Complaint:** Complaint means any written, electronic, or oral communication that
842 alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or
843 performance of a medical device or health information technology after it is released for
844 distribution.

845 **Customer Incident:** An occurrence from a customer’s use of software, products or services that
846 actually or potentially results in adverse consequences to (adverse effects on) (poses a threat to)
847 an information system or the information that the system processes, stores, or transmits and that
848 may require a response action to mitigate the consequences.

849 **Customer Security Documentation:** Security information provided to customers to enable
850 more robust risk assessments, identify configurable security controls, and allow them to better
851 protect their systems.

852 **Customer Security Requirements:** A user, or potential user, of a system’s functional and non-
853 functional requirements that achieve the security attributes of a system.

854 **Decommissioning:** The first physical process in the disposition process and includes proper
855 identification, authorization for disposition, and sanitization of the equipment, as well as removal
856 of Patient Health Information (PHI) or software, or both.

857 **Design:** A process of defining the architecture, modules, interfaces and data for a system to
858 satisfy specified requirements.

859 **Design control:** The application of a formal methodology used to conduct product development
860 activities.

861 **Design Input Requirements:** The physical and performance characteristics of a product that are
862 used as the basis for product design.

863 **Dynamic Code Analysis:** The testing and evaluation of a program by executing data in real-
864 time. The objective is to find errors in a program while it is running, rather than by repeatedly
865 examining the code offline.

866 **End of Life:** Indicates that the product is in the end of its useful life, as defined by the vendor,
867 and a vendor stops marketing, selling, or making major design changes in sustaining the product.

868 **End of Support:** A point beyond which the product manufacturer ceases to provide support,
869 which may include cybersecurity support, for a product or service.

870 **Exceptions:** An instance when a cybersecurity risk is identified (both pre- and post-launch of the
871 product) and the vendor determines that no action is needed.

872 **Failure Mode and Effects Analysis (FMEA):** A step-by-step approach for identifying all
873 possible failures in a design, a manufacturing or assembly process, or a product or service.

874 **Fuzz Testing:** A software testing technique, often automated or semi-automated, that involves
875 providing invalid, unexpected, or random data to the inputs of a computer program. The program
876 is then monitored for exceptions such as crashes, failing built-in code assertions or for finding
877 potential memory leaks. Fuzzing is commonly used to test for security problems in software or
878 computer systems and is a type of robustness testing.

879 **Harm:** Injury or damage to the health of people, or damage to property or the environment.

880 **Hazard:** Potential source of harm.

881 **Hazard Analysis:** The first step in a process used to assess risk and used to identify different
882 types of hazard.

883 **Incident Response:** Actions taken to mitigate or resolve a security incident.

884 **Internal/External Security Audit:** Review and examination of data processing system records
885 and activities to test for adequacy of system controls, to ensure compliance with established
886 security policy and operational procedures, to detect breaches in security, and to recommend any
887 indicated changes in control, security policy, and procedures.

888 **Malware:** A program that is inserted into a system, usually covertly, with the intent of
889 compromising the confidentiality, integrity, or availability of the data, applications, or operating
890 system. This includes both known and unknown (Zero Day) viruses, spyware, ransomware, and
891 other forms of malicious code that exploit vulnerable systems.

892 **Patch Management:** The systematic monitoring, identification, assessment, remediation,
893 deployment, and verification of operating system and application software code updates. These
894 updates are known as patches, hot fixes, and service packs to operating systems, third-party
895 products and components, and in-house developed software.

896 **Patient Harm:** Physical injury or damage to the health of patients, including death.
897 Cybersecurity exploits (e.g. loss of authenticity, availability, integrity, or confidentiality) of a
898 device may pose a risk to health and may result in patient harm.

899 **Patient Safety:** The prevention of harm to patients including that which may occur from
900 cybersecurity related events.

901 **Penetration Testing:** A test methodology in which assessors, using all available documentation
902 such as system design and working under specific constraints, attempt to circumvent the security
903 features of an information system.

904 **Preliminary Hazard Analysis (PHA):** A technique used in the early stages of system design. It
905 focuses on identifying apparent hazards, assessing the severity of potential accidents that could
906 occur involving the hazards, and identifying safeguards for reducing the risks associated with the
907 hazards.

908 **Product Lifecycle:** Managing the entire lifecycle of a product from inception, through
909 engineering design and manufacture, to service and disposal of manufactured products.

910 **Product Security Risk Assessment:** Overall process of risk analysis and a risk evaluation for
911 security issues found in products using impact to confidentiality, integrity, and availability to
912 patients, customers, and vendor to determine the acceptability of the risk.

913 **Remediation:** Countermeasures to reduce a cyber asset's susceptibility to cyber-attack over a
914 range of attack tactics, techniques, and procedures.

915 **Remediation Planning:** Planning of processes and actions by which organizations identify and
916 resolve threats to their system.

917 **Remote Access:** Access to a product or an organization's non-public information system by an
918 authorized user such as Service and Support communicating through an external network.

919 **Remote Support:** Support activities conducted by individuals communicating through an
920 external network (e.g., the Internet).

921 **Removable Media:** Portable electronic storage media such as magnetic, optical, and solid-state
922 devices, which can be inserted into and removed from a computing device and used to store text,
923 video, audio, and image information. Such devices have no independent processing capabilities.
924 Examples include hard disks, floppy disks, zip drives, compact disks, thumb drives, pen drives,
925 and similar USB storage devices.

926 **Risk Management:** Risk management is an integral part of the medical device product
927 development lifecycle. It is a systematic application of management policies, procedures and
928 practices to the tasks of analyzing, evaluating, controlling, and monitoring risk.

929 **Robustness Testing:** A testing methodology to detect the vulnerabilities of a component under
930 unexpected inputs or in a stressful environment.

931 **Secure Coding Standards:** Guidelines for writing software code that mitigates common
932 security flaws specific to a programming language or in general to all software.

933 **Security Incident:** An event that may indicate that a device's data and security may have been
934 compromised. This includes, but is not limited to:

935 • Attempts to gain unauthorized access to a system or its data
936 • Unwanted disruption or denial of service
937 • Unauthorized use of a system for the processing or storage of data
938 • Changes to system hardware, firmware or software characteristics without owner's
939 knowledge, instruction or consent

940 **Security Management Plan:** Used to document all framework components carried out through
941 the design process and post commercialization. May also capture technical and process gaps,
942 including exceptions. May be incorporated in a product risk management file or equivalent.

943 **Security Requirements:** A set of design-level requirements that comprise a product or other
944 commercial offerings, ensure security issues are mitigated in both software and system
945 components during design control, and are processed through Risk Management.

946 **Sensitive Information and Data:** Protected health information (PHI), personally identifiable
947 information (PII), proprietary software source code or business logic, configuration parameters,
948 user credentials, cryptographic keys, quality control and calibration results.

949 **Static Code Analysis:** The automated analysis of software code for security flaws and adherence
950 to a secure coding standard.

951 **System Hardening Standards:** A documented process or mechanism for securely configuring
952 or implementing commonly used technologies.

953 **Third-Party Entities:** External individuals and organizations such as vendor and suppliers
954 involved with products or acquisition, that collaborate at any point in the product lifecycle,
955 including acquisition, development and servicing.

956 **Threat Modeling:** Structured activity for identifying and managing threats.

957 **Threat Monitoring:** Solutions or processes dedicated to continuously monitoring systems,
958 networks and endpoints for signs of a security threat such as intrusions or data exfiltration.

959 **Threat Source:** The intent and method targeted at the intentional exploitation of a vulnerability
960 or a situation and method that may accidentally trigger a vulnerability.

961 **Uncontrolled Risk:** Uncontrolled risk is present when there is unacceptable residual risk of
962 patient harm due to inadequate compensating controls and risk mitigations.

963 **Validation:** Establishing by objective evidence that specified requirements conform with user
964 needs and intended use(s).

965 **Vendors:** Includes medical device manufacturers and health IT vendors.

966 **Verification:** Confirmation by objective evidence that the results of the design effort meet the
967 design input.

968 **Vulnerability:** A weakness in an information system, system security procedures, internal
969 controls, or implementation that could be exploited or triggered by a threat source.

970 **Vulnerability Disclosure:** Policy practiced by organizations as well as individuals regarding the
971 disclosure or publishing of information about security vulnerabilities and exploits pertaining to a
972 computer system, network or software.

973 **Vulnerability Scanning:** The automated analysis and detection of vulnerabilities such as
974 missing patches and misconfiguration in operating systems and other third-party software.

975

976 **Appendix C: Roles and Responsibilities**

977 Numerous stakeholders may leverage and benefit from the security activities and processes
978 described in this document. To provide additional context, the roles and responsibilities of these
979 stakeholders are described in this appendix section.

980 **For customer stakeholders**

981 1. **Patients:** Review security documentation provided by vendors and healthcare providers
982 for consumer products and in-home environments such that cybersecurity risks are
983 understood and managed.

984 2. **Healthcare Providers:** Assess the risk of new information systems entering their
985 facilities; manage risks over the lifecycle of these information systems, including
986 monitoring of vulnerability disclosures, maintaining patches, securing network
987 environments and enterprise systems; and provide training for their associates on their
988 roles for managing cybersecurity. Also referred to as healthcare delivery organizations
989 (HDOs).

990 **For vendor stakeholders**

- 991 1. **Medical Device Manufacturers:** Responsible for implementing security throughout the
992 design, development, and complaint handling for medical devices. In addition,
993 responsible for providing timely communication to customers in the form of product
994 security documentation, vulnerability disclosures, and the availability of security patches.
- 995 2. **Health IT Vendors:** Responsible for implementing security throughout the design,
996 development, and complaint handling for healthcare information technology. In addition,
997 responsible for providing timely communication to customers in the form of product
998 security documentation, vulnerability disclosures, and the availability of security patches.
- 999 3. **Product Security:** Creation and maintenance of policies, procedures, tooling, guidance,
1000 training and awareness for product security across business units and functions. Product
1001 security will support product security risk assessments, automated security testing,
1002 penetration testing, remediation planning services for R&D and complaint handling.
- 1003 4. **Quality:** Ensures the framework is aligned and consistent with other corporate policies,
1004 as well as global regulations and standards for product development, risk management,
1005 manufacturing, and support. Quality, jointly with product security, will ensure adherence
1006 to the framework as with any other quality policy such as risk management and reporting
1007 requirements.
- 1008 5. **Research and Development (R&D):** Responsible for incorporating security in
1009 budgeting and resource planning; provides technical information for product security risk
1010 assessment; establishes design requirements in the development process and throughout
1011 the product lifecycle including post-commercialization maintainability. R&D will
1012 maintain record of security defects in accordance with the business unit quality
1013 management systems including design control and risk management procedures.
- 1014 6. **Product & Portfolio Management (PM, PPM):** Responsible for ensuring product
1015 security is incorporated in budget, resource, project, and roadmap planning activities
1016 throughout the product lifecycle.
- 1017 7. **Complaint Handling Unit:** Responsible for identifying complaints that have a product
1018 security impact and proper escalation of complaints.
- 1019 8. **Service and Support:** Ensure proper response to security incidents and events with
1020 products at customer sites, including proper documentation records as per business unit
1021 complaint handling procedures. Secure service assets, maintain validated security updates
1022 and ensure secure implementation, periodic reporting of security incident and events and
1023 security update tracking.
- 1024 9. **Business Unit and Regional Leadership:** Responsible for communication, compliance
1025 and adherence of the framework at the regional and local business levels. This may
1026 include the creation of local policies that align with and supplement where needed due to
1027 regional laws and regulation the over-arching framework.
- 1028 10. **Legal:** Provides business units with guidance on incident response, adherence to local
1029 security and privacy laws to ensure legal content meets policies.
- 1030 11. **Privacy:** Ensures the appropriate protection of data, such as information from or about
1031 our employees, our customers, and users of our products worldwide.
- 1032 12. **Regulatory:** Provides business units and product security with guidance on local
1033 security and privacy regulation, including any upcoming changes to those regulations.

- 1034 13. **Information Security:** Ensures vendor managed assets, including but not limited to
 1035 laptops, desktop computers, servers, removable media, and networks that interact with
 1036 products align and adhere to the vendor information security policy.
 1037 14. **Third-Party Entities:** Adhere to requirements in the framework and vendor information
 1038 security procedure. Document any exceptions in design history and/or risk management
 1039 files.

1040

1041 **Appendix D: Drafting of the Joint Security Plan**

1042 The intent and purpose of this appendix section is to outline and explain the drafting process and
 1043 authoritative sources used to address traceability to US and International standards for the
 1044 Medical Device and Health IT Joint Security Plan.

1045 In November of 2017, with facilitation by the Healthcare Sector Coordinating Council (HSCC),
 1046 an initial draft of the Joint Security Plan was developed by a group of medical device
 1047 manufacturers, health IT vendors, and FDA representatives.

1048 In February of 2018, through the Health Information Sharing and Analysis Center (H-ISAC) and
 1049 HSCC, a group of healthcare providers was invited to participate in the drafting process of the
 1050 Joint Security Plan.

1051 Following the review by medical device manufacturers, health IT vendors, and healthcare
 1052 providers, the HSCC invited government and policymakers to provide feedback and promote use
 1053 of the Joint Security Plan among all stakeholders referenced in the document.

1054 There are many different authoritative sources which were used to develop and/or can be used to
 1055 achieve aspects of the Joint Security Plan. The following is a list of those sources and the
 1056 associated section in the Joint Security Plan:

1057

1058

JSP Framework Overview	
Health Industry Cybersecurity Practices (HICP): Managing Threats and Protecting Patients publication	https://www.phe.gov/Preparedness/planning/405d/Documents/HICP-Main-508.pdf
Risk Management	
AAMI TIR 57	http://www.aami.org/productspublications/ProductDetail.aspx?ItemNumber=3729
IEC 80001-1	https://www.iso.org/standard/44863.html
NIST CSF	https://www.nist.gov/cyberframework
An Introduction to Computer Security: the NIST Handbook	https://nvlpubs.nist.gov/nistpubs/legacy/sp/nistspecialpublication800-12.pdf

ISACA Risk IT Framework for Management of IT Related Business Risks	http://www.isaca.org/Knowledge-Center/Risk-IT-IT-Risk-Management/Pages/default.aspx
ISO 14971:2007 Medical devices -- Application of risk management to medical devices	https://www.iso.org/standard/38193.html
Risk Assessment	
Common Vulnerability Scoring System	https://www.first.org/cvss/user-guide
NIST Special Publication 800-30 Revision 1.0 2012 Guide For Conducting Risk Assessments	https://nvlpubs.nist.gov/nistpubs/Legacy/SP/nistspecialpublication800-30r1.pdf
Design Control	
Content of Premarket Submissions for. Management of Cybersecurity in. Medical Devices	https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm356190.pdf
UL 2900-1 Standard for Software Cybersecurity for Network-Connectable Products, Part 1: General Requirements	https://standardscatalog.ul.com/standards/en/standard/2900-1_1
UL 2900-2-1 Software Cybersecurity for Network-Connectable Products, Part 2-1: Particular Requirements for Network Connectable Components of Healthcare and Wellness Systems	https://standardscatalog.ul.com/standards/en/standard/2900-2-1_1
NIST SP 800-160 Systems Security Engineering. Considerations for a Multidisciplinary Approach in the. Engineering of Trustworthy Secure Systems	http://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-160.pdf
Catalog of Control Systems Security: Recommendations for Standards Developers	https://ics-cert.us-cert.gov/sites/default/files/documents/CatalogofRecommendationsVer7.pdf
Secure Architecture Design	https://ics-cert.us-cert.gov/Secure-Architecture-Design
NIST Cybersecurity Practice Guide SP 1800-8, Wireless Infusion Pumps	https://nccoe.nist.gov/sites/default/files/library/sp1800/hit-infusion-pump-nist-sp1800-8a-draft.pdf
NIST SPECIAL PUBLICATION 1800-8B Volume B:	https://nccoe.nist.gov/sites/default/files/library/sp1800/hit-infusion-pump-nist-sp1800-8b-draft.pdf

Approach, Architecture, and Security Characteristics	
Secure Software Development Life Cycle Processes	https://www.us-cert.gov/bsi/articles/knowledge/sdlc-process/secure-software-development-life-cycle-processes
OWASP Security By Design Principles	https://www.owasp.org/index.php/Security_by_Design_Principles#Security_principles)
Standards and Testing	
DISA Security Technical Implementation Guides	https://iase.disa.mil/stigs/Pages/a-z.aspx
NIST Checklists	https://www.nist.gov/programs-projects/national-checklist-program
NSA Guides	https://www.nsa.gov/ia/mitigation_guidance/security_configuration_guides/
CIS Benchmarks	https://benchmarks.cisecurity.org/downloads/benchmarks/
SEI CERT Coding Standards	https://www.securecoding.cert.org/confluence/display/seccode/SEI+CERT+Coding+Standards
OWASP Secure Coding Practices	https://www.owasp.org/index.php/OWASP_Secure_Coding_Practices_-_Quick_Reference_Guide
MS Secure Coding Guidelines	https://msdn.microsoft.com/en-us/library/fkytk30f(v=vs.110).aspx
Improving Industrial Control System Cybersecurity with Defense-in-Depth Strategies	https://ics-cert.us-cert.gov/sites/default/files/FactSheets/ICS-CERT_FactSheet_Defense_in_Depth_Strategies_S508C.pdf
Vulnerability and Patch Management	
ISO/IEC 30111	https://www.iso.org/standard/53231.html
NIST National Vulnerability Database	https://www.nist.gov/programs-projects/national-vulnerability-database-nvd
CVE Details	https://www.cvedetails.com/index.php
Department of Homeland Security ICS-CERT Division	https://ics-cert.us-cert.gov/advisories
Carnegie Mellon University Software Engineering Institute	https://www.kb.cert.org/vuls/
Guide for Cybersecurity Event Recovery	https://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-184.pdf

SANS Vulnerability Management	https://www.sans.org/reading-room/whitepapers/projectmanagement/building-vulnerability-management-program-project-management-approach-35932
Customer Security Documentation	
HIMMS/NEMA Manufacturers Disclosure Statement for Medical Device Security (MDS2)	http://www.himss.org/resourcelibrary/MDS2
Software Identification Tags (SWID)	https://nvd.nist.gov/products/swid
Common Platform Enumeration (CPE)	https://csrc.nist.gov/projects/security-content-automation-protocol/specifications/cpe/
Reporting Considerations	
Postmarket Management of Cybersecurity in Medical Devices	https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm482022.pdf
Security Incident Response and Communication	
ISO/IEC 29147	https://www.iso.org/standard/72311.html
Medical Device Cybersecurity Report: Advancing Coordinated Vulnerability Disclosure	http://mdic.org/wp-content/uploads/2018/10/MDIC-CybersecurityReport.pdf
Evaluating Joint Security Plan Progress and Maturity	
Capability Maturity Model Index	http://cmmiinstitute.com/capability-maturity-model-integration
Cyber Threat Source Descriptions	https://ics-cert.us-cert.gov/content/cyber-threat-source-descriptions
Overview of Cyber Vulnerabilities	https://ics-cert.us-cert.gov/content/overview-cyber-vulnerabilities

1059

United States of America	
21 CFR 806	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=806&showFR=1
HIPAA – HITECH	https://www.hhs.gov/hipaa/for-professionals/special-topics/hitech-act-enforcement-interim-final-rule/index.html
National Infrastructure Protection Plan (NIPP)	https://www.dhs.gov/cisa/national-infrastructure-protection-plan

European Union	
93/42/CE	https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1993L0042:20071011:en:PDF
EU General Data Protection Regulation (GDPR)	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016R0679
Medical Device Regulations (MDR)	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC
Network and Information Systems (NIS) Directive	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.194.01.0001.01.ENG&toc=OJ:L:2016:194:TOC
Canada	
The Personal Information Protection and Electronic Documents Act (PIPEDA)	https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/

1060

1061 **Appendix E: Example Design Input Requirements for** 1062 **Security**

1063 The controls and features included in device design are informed by the device type, design, use
1064 environment, and intended use or functionality. As such, there is no one size fits all set of design
1065 inputs that should be utilized. Design inputs highlighted here in this appendix section are not
1066 intended to be comprehensive; rather, they serve as examples of input requirements that could be
1067 considered within the context of use for a given device. These design input requirements are
1068 categorized by OWASP Security Design Principles.

1069

1070 **● Minimize Attack Surface**

- 1071 1. The system shall restrict access of removable media to what is necessary for
1072 intended use.
- 1073 2. Execution of software on the system shall be restricted to explicitly authorized or
1074 validated software components.
- 1075 3. The system shall provide capability to anonymize exported data such that an
1076 individual or customer is not identifiable.
- 1077 4. Ports, protocols, services and addresses available on the system and its network
1078 connection shall be restricted to the minimum necessary for intended use and
1079 configurable locally by authorized user.
- 1080 5. The system shall be capable of enabling and disabling particular protocol stacks,
1081 individual ports and services, and contains manageable host-based firewall.
- 1082 6. The system shall provide capability to explicitly enable or disable remote access
1083 to the system.

- 1084 7. The system shall notify users to change default passwords after initial use.
1085 8. The system shall be capable of restricting repeated and failed user access
1086 attempts.
- 1087 ● **Establish Secure Defaults**
 - 1088 9. The system shall have the ability to require a minimum password length.
 - 1089 10. The system shall have the ability to require a minimum password complexity.
 - 1090 11. The system shall have the ability to require periodic password renewal.
 - 1091 12. The system shall have the ability to restrict password reuse.
 - 1092 13. The system shall have the capability to automatically or manually back-up data
1093 necessary for intended use locally or to an external location.
 - 1094 14. All sensitive information and data shall be encrypted in transit and at rest using an
1095 industry-accepted encryption mechanism and practice.
 - 1096 15. The system shall prominently notify users when sensitive information and data
1097 are displayed on screen or if encryption is disabled in transit.
 - 1098 16. The system shall have routine functionality for handling exceptions, errors and
1099 aborts that does not expose sensitive information and data.
 - 1100 17. The system shall enforce strict order of execution during system start and end.
 - 1101 18. All remote or local user activity which interacts with sensitive information and
1102 data as well as critical functions on the system shall be recorded in an audit log.
 - 1103 19. All audit log entries shall include a start and end date-timestamp, user ID,
1104 role/privileges at time of access, success/failure and a description of the action
1105 performed.
 - 1106 20. The audit log shall locally retain an individual entry for a configurable period of
1107 time or allocation of file system space.
 - 1108 21. The system shall provide capability for a user to reset their own password or
1109 administrative reset, which is logged.
 - 1110 22. The system shall provide the ability to create and assign a unique user ID and
1111 password to each remote or local user.
 - 1112 ● **Principle of Least Privilege**
 - 1113 23. Execution of software on the system shall be limited to the minimum privileges
1114 necessary.
 - 1115 24. The system shall support the creation and assignment of roles that grant the
1116 minimum user privileges necessary for intended use of data and functions.
 - 1117 ● **Principle of Defense in Depth**
 - 1118 25. The system shall support multiple factors for user authentication and capable of
1119 centralized authentication.
 - 1120 26. The system shall provide capability to prevent the execution of known malicious
1121 software.
 - 1122 27. The system shall be capable of manually or automatically locking the display and
1123 requiring user authentication after a configurable period of user inactivity in order
1124 to continue use such that sensitive information and data are not visible.
 - 1125 28. The system shall provide capability for a user to reset their own password or
1126 administrative reset, which is logged.
 - 1127 ● **Fail Securely**
 - 1128 29. The system shall be capable of restoring functionality to an operational state.
1129

- 1130 ● **Don't Trust Services**
- 1131 30. The integrity and composition of all data as input or output of the system shall be
- 1132 validated such that modification is detected and/or rejected.
- 1133 31. All remote or local access to the system by user or an external system shall be
- 1134 authenticated prior to granting access to data or functions.
- 1135 ● **Separation of Duties**
- 1136 32. The audit log shall be restricted in access to only authorized users.
- 1137 33. The audit log shall be exportable and readable by authorized users and have the
- 1138 capability to integrate with security information and event management for real-
- 1139 time analysis.
- 1140 ● **Avoid Security by Obscurity**
- 1141 34. The security of a system shall not rely upon knowledge of the source code or
- 1142 shared hard coded credentials being kept secret.
- 1143 ● **Keep Security Simple**
- 1144 35. The system shall allow security controls to be configured with no significant
- 1145 downtime and centrally managed by authorized users.
- 1146 ● **Fix Security Issues Correctly**
- 1147 36. The system shall support authorized updates to mechanisms for controlling the
- 1148 execution of authorized or malicious software.
- 1149 37. Components of the system shall support software updating and patches with no
- 1150 significant downtime using standard centralized patch management systems.
- 1151

1152 **Appendix F: Example Third-Party Security Agreement**

1153 It is important for vendors to consider the security of various components in their supply chain at
 1154 the time of procurement. This appendix section specifies security requirements applicable to
 1155 third-party suppliers that provide product development and post-market product management
 1156 services to a given vendor.

1157 The supplier is responsible for understanding the risk of [Company] and [Company's]
 1158 customers' information and products it will access, process, manage, or store in the performance
 1159 of services to [Company], and [Company's] customers. Compliance with the Association for the
 1160 Advancement of Medical Instrumentation's (AAMI) "Technical Information Report (TIR) 57 -
 1161 Principles for medical device security—Risk management" is recommended for meeting these
 1162 objectives.

1163 **1. PRODUCT DEVELOPMENT**

- 1164 1.1 Cybersecurity requirements are evaluated and documented during product design.
- 1165 1.2 Cybersecurity threats and risks are evaluated and documented as part of a risk
- 1166 analysis process during product design.
- 1167 1.3 Cybersecurity testing is completed as a part of verification and validation
- 1168 activities. Testing includes, but is not limited to, the following:
- 1169 a) Vulnerability scanning
- 1170 b) Static/binary code scanning
- 1171 c) Fuzz testing
- 1172 d) Customized test cases to evaluate defined cybersecurity
- 1173 requirements

- 1174 e) Penetration tests
1175 1.4 Cybersecurity penetration test is performed before the product is launched.
1176 1.5 Defects identified during security testing shall be documented and evaluated for
1177 correction based on risk analysis process.
1178 1.6 A software inventory or bill of materials shall be documented identifying all
1179 software of unknown provenance (SOUP) and third-party software components in
1180 a device and any backend support and specialist development systems.
1181 a) A security assessment of third party and SOUP components is
1182 performed to determine version and patches are up to date and existing
1183 vulnerabilities are evaluated for risk and corrective action.
1184 b) At the request of [Company] product owners and stakeholders,
1185 documentation and/or evidence of the above shall be made available.
1186 c) At the request of [Company] product owners and stakeholders,
1187 source code and or binary files shall be made available.
1188 d) Licensing arrangements for third party software, that establishes
1189 permissions for use, longevity and liabilities shall be negotiated with
1190 [Company] prior to incorporating such code in code developed for
1191 [Company].
1192 e) Code associated with open source licenses shall be carefully
1193 considered and declared to [Company] and be appraised for the potential
1194 for [Company] to declare or reveal associated intellectual property in the
1195 form of bespoke, contracted code, at any time in the future.
1196

1197 2. POST-MARKET PRODUCT MANAGEMENT

- 1198 2.1 Operating procedures are documented and approved for addressing cybersecurity
1199 patching, updating and remediation.
1200 2.2 A process is defined to facilitate ongoing product change management throughout
1201 the lifecycle of the device.
1202 2.3 A separate testing environment is established for evaluation of patches and
1203 incidents, including necessary devices and connection to backend systems.
1204 2.4 Security measures shall be reviewed including threats, breaches, user access, new
1205 vulnerability reports, assessment of risks and necessary responses, at least
1206 annually or when there is a material change in business practices.
1207 2.5 Training materials and a training plan for administration of the system including
1208 security critical roles and functions shall be established.
1209 2.6 Termination and transfer of people resources from system access, key system
1210 knowledge, and process responsibilities shall be accomplished through
1211 documented processes.
1212 2.7 Product documentation that is publicly available shall be identified and
1213 documented at least annually.
1214 2.8 A process for handling (investigating and remediating) potential vulnerabilities in
1215 products is defined.
1216 2.9 An incident mitigation and response plan is developed, including a timeframe
1217 during which mitigation occurs.

- 1218 2.10 Complaint handling systems include notification to [Company] product owner
1219 and [Company's] product security organization if a cybersecurity complaint is
1220 reported by a customer.
- 1221 2.11 The [Company] product owner and [Company's] product security organization
1222 shall be immediately notified if a cybersecurity issue is identified in a product.
- 1223 2.12 At the request of [Company] product owners and stakeholders, documentation
1224 and/or evidence of the above shall be made available.
1225

1226 **Appendix G: Example Customer Security Documentation**

1227 Customers require security documentation to enable more robust risk assessments, identify
1228 configurable security controls, and allow them to better protect their systems. This appendix
1229 section provides an overview of items that may be included in Customer Security
1230 Documentation. The following are examples of the types of information which may be included
1231 in documentation of security for medical devices or health IT:

- 1232 • Product Description
- 1233 • Hardware Specifications
- 1234 • Operating Systems
- 1235 • Third-party Software
- 1236 • Network Ports and Services
- 1237 • Sensitive Information and Data Transmitted
- 1238 • Sensitive Information and Data Stored
- 1239 • Network and Data Flow Diagram
- 1240 • Malware Protection
- 1241 • Authentication
- 1242 • Network Controls
- 1243 • Physical Controls
- 1244 • Encryption
- 1245 • Audit Logging
- 1246 • Remote Connectivity
- 1247 • Service Handling
- 1248 • End-of-Life and End-of-Support
- 1249 • Secure Coding Standards
- 1250 • System Hardening Standards
- 1251 • Risk Summary
- 1252 • Third Party Certification or Attestation
- 1253 • Manufacturer's Disclosure Statement for Medical Device Security

1254 1255 **Product Description**

1256 [Insert basic description of function or purpose of the product or solution. Photo is optional, but
1257 recommended.]

1258 1259 **Hardware Specifications**

1260 [List hardware components and specs]

1261 • [List]

1262 • [List]

1263 **Operating Systems**

1264 [List hardware operating systems and versions]

1265 • [List]

1266 • [List]

1267 **Third-party Software**

1268 [Also referred to as a Bill of Materials (BOM), includes a list of third-party software and version
1269 numbers where applicable. Having a cybersecurity bill of materials will aid customers in
1270 mitigating cybersecurity concerns on their healthcare technologies and ultimately to the
1271 systems/networks these technologies are attached to. The following are example attributes that
1272 would enable customers to leverage a bill of materials in protecting their assets.

1273 Detailed attributes include:

1274 • All commercial, open source, and custom code must be included

1275 • Commercial technology components (e.g. processors, network cards, sound cards,
1276 graphic cards, memory) must be included

1277 • The software list will be codified using an industry standard, such as Common Platform
1278 Enumeration (CPE), Software Identification tag (SWID), or Software Package Data Exchange
1279 (SPDX) that allows the software list to be searched and used to check against vulnerability feeds

1280 • The list will be available in an electronic format that allows bulk uploading into common
1281 asset inventories, vulnerability management systems and configuration management databases.

1282 • The BOM will be provided to a customer both upon a purchase and after significant
1283 software or hardware upgrades

1284 • Vendors will maintain a BOM for all product versions that will be accessible remotely by
1285 customers]

1286

Vendor and Name	Version	Description
[e.g. Microsoft Windows 10]	[e.g. 1607]	[e.g. Long Term Servicing Branch]

1287 **Network Ports and Services**

1288 [List Network Ports and Services]

Port	Protocol	Service Name	Description of Service	Encrypted	Open/Closed
XXX	XXX	XXXXX	XXXXX	XXX	XXX

1289

1290 **Sensitive Information and Data Transmitted**

1291 [List sensitive information and data transmitted. This can include PHI/PII/Potential access to
1292 wireless credentials, etc.]

1293 • [List]

1294 • [List]

1295 **Sensitive Information and Data Stored**

1296 [List sensitive information and data stored. This can include PHI/PII/Potential access to wireless
1297 credentials, etc.]

1298 • [List]

1299 • [List]

1300 **Network and Data Flow Diagram**

1301 [Provide a diagram that describes how the product resides in a customer environment, showing
1302 the system components (1 or N computers, routers, switches, adjacent systems, remote
1303 connectivity) types of connectivity (e.g. RS232, RJ45, Serial to TCP/IP conversion), what types
1304 of data is in transit and at rest (e.g. PHI, QC, config data), and how these are secured (e.g. in
1305 transit IPsec, HTTPS/TLS, WIFI WPA2PSK; at rest BitLocker, SQL TDE)

1306 **Important:** include if the device makes PHI/PII available via network or point-to-point
1307 connection (wired/wireless)?

1308 • Is connected data encrypted in transit?

1309 • Does service have network or p-to-p access to PHI (remote or in-room)?]

1310

1311 **Malware Protection**

1312 [Describe and recommend the anti-malware measures available (e.g. validated AV solutions, AV
1313 partners, how AV is managed, application whitelisting like AppLocker or McAfee Embedded
1314 Control, advanced antimalware solutions, software restriction policies)]

1315

1316 **Patch Management**

1317 [Describe and recommend the method in which we maintain, provide and deploy patch updates
1318 for this product. Examples include, “Patches are installed by a field service engineer during a
1319 routine service visit or during the yearly service visit. In the even that there is no patch
1320 management solution in place, also communicate this in this section.]

1321

1322 **Authentication & Authorization**

1323 [Describe and recommend the controls that customers have with user’s authenticating and
1324 granting permissions to features and functionality, how users are managed, the default use
1325 accounts on the system and how to change and configure accounts. This includes the ability to
1326 disable user accounts]

1327

1328 **Network Controls**

1329 [Describe and recommend the firewall rules, IPSec rules, host file restrictions, browser Internet
1330 access restrictions, MAC and IP address filtering)]

1331
1332 **Encryption**

1333 [Describe and recommend where and how encryption is applied on the system (e.g. all network
1334 traffic is TLS 1.2, at rest is BitLocker with AES 256)]

1335
1336 **Audit Logging**

1337 [Describe the audit logging process, where they are stored, what an auditable event entails, who
1338 has access to audit logs and any file permissions. Describe if audit logs are synchronized with
1339 reliable time sources and have the proper time zone set or no time offset (e.g., GMT or UTC).

- 1340
- 1341 • What is the typical and maximum number of records retained on the device when in use?
 - 1342 • Do users have a means to irreversibly delete audit log records in the device?
 - 1343 • Does Service ever retain copies of PHI/PII data (is it encrypted by service) in audit logs?
 - 1344 • Application Auditing
 - 1345 ○ Audit file location: E:\PieRoot\Logfiles*.pld
 - 1346 ○ Audit files hashed with SHA256 when complete for integrity.
 - 1347 ○ Auditable Events:
 - 1348 ▪ Service Start/Stop
 - 1349 ▪ User login/logout
 - 1350 ▪ User session created/destroyed.
 - 1351 ▪ User login from multiple workstations.
 - 1352 ▪ Client application connect/disconnect with IP address and port.
 - 1353 ▪ Failed client connection attempts.
 - 1354 ▪ Changes in application configuration.
 - 1355 ▪ Failed/successful attempts to access, modify, or delete security objects;
e.g. roles, permissions, etc.
 - 1356 • Audit file permissions:
 - 1357 ○ Administrators group: Read.
 - 1358 ○ Auditors group: Read.
 - 1359 ○ DB Auditors group: Full control.
 - 1360 ○ DB Administrators group: Full control.
 - 1361 ○ Virtual/Managed service accounts (audit file creators): Full control.
 - 1362 ○ Users: None.]

1363 **Remote Connectivity**

1364 [Describe the nature of remote connectivity, what ports, protocols, URLs and endpoints for
1365 communication as well as security measures applied to the remote connection (e.g. TLS)]

1366
1367 **Service Handling**

1368 [Describe what routine maintenance service personnel perform, what security policies and
1369 procedures they follow (e.g. never take PHI or PII, on-site authorization protocol, encrypted
1370 Removable Media, hardened service laptops, whether or not service laptops connect to product,

1371 routine AV update during visit, secure installation/implementation principles, service
1372 authentication to product, decommissioning process, once decommissioned how the product hard
1373 drive is wiped, how the product is recovered from the field or destroyed, and what customer data
1374 and features service personnel interact with)]

1375
1376 **End-of-Life and End-of-Support**

1377 [Describe the life cycle of the product in relation to when it will no longer be sold, updated, and
1378 supported. Provide dates if available otherwise describe how EOL/EOS is communicated.]

1379
1380 **Secure Coding Standards**

1381 [Describe the secure coding standards used]

- 1382 • [List the industry secure coding standards used during software development (e.g. SEI
1383 CERT Java Secure Coding Standard)]

1384 **System Hardening Standards**

1385 [Describe the secure hardening standards used, may also create appendix to list out standards
1386 used.]

Name of Standard	Version Number	Source of Standard
[Insert name of standard]	[Insert version number]	[Insert URL]

1387
1388 **Risk Summary**

1389 [This section should contain a summary of risks found within a penetration test, remediation
1390 report, or other topics and compensating controls that correspond to additional risks outlined in
1391 the product security white paper. This may also include any findings from application scans.]

1392
1393 **Appendix H: Example Organizational Structure**

1394 The intent of this appendix section is to provide an example of roles and responsibilities within
1395 organizations to support the adoption and continuous improvement of cyber security for medical
1396 devices and health IT:

1397
1398 **Medical Device Manufacturers and Health IT Vendors**

- 1399 • **Chief Product Security/Cybersecurity Officer:** Responsibility to drive product and
1400 solution security throughout a vendor organization including identifying best practices
1401 and companywide technical standards, processes, and policies, for overall governance or
1402 guidance. In addition, this individual will advise executive management, product
1403 management, project management, R&D heads and manufacturing heads with regard to
1404 security for all products, solutions and services. Responsible for implementing pre-
1405 market product security design and post-market support including cybersecurity events
1406 and incidents for products in scope. Independent of Information Security and in
1407 cooperation with the CEO, this individual will advise appropriate processes and
1408 structures to introduce security into products, solutions and services.
- 1409 • **Product Security/Cybersecurity Engineering**

- 1410 ○ Security Architects: This person will work with R&D, service, and quality
1411 organizations to research common security vulnerabilities and their remediation;
1412 develop procedures to incorporate hardening into product development; work
1413 with individual product teams in securing their products; and proactively educate
1414 teams across the company on security best practices for products under
1415 development.
- 1416 ○ Penetration Testers: This person will perform security penetration testing, ethical
1417 hacking and red team activities in order to identify unique and common
1418 vulnerabilities in products under development. This includes performing
1419 vulnerability analysis and research, formalizing security testing procedures in the
1420 product lifecycle, performing penetration testing with remediation plans and
1421 formal reporting, and supporting red team, covert, and security activities to test
1422 organizational readiness.
- 1423 ● **Product Security/Cybersecurity Incident Response**
- 1424 ○ Incident Responder: This person will manage technical strategy, process,
1425 timelines, resources and progress for incidents relating to products at customer
1426 sites or with security researchers.
- 1427 ○ Vulnerability Manager: This person will track the escalation, follow-up, and
1428 remediation of vulnerabilities throughout the product lifecycle.
- 1429 ● **Product Security/Cybersecurity Program Management**
- 1430 ○ Policy and Compliance Analyst: This person will ensure the adoption and
1431 continuous improvement of security policies and procedures for products in
1432 compliance with industry standards and regulations.
- 1433 ○ Strategic Program Manager: This person will work cross-functionally to create
1434 programs and initiatives for establishing training, awareness, and fundamental
1435 capabilities for improving security of products.
- 1436 ● **Product Security Testing** – Responsible for assessing and testing products in
1437 development and in the market so as to understand cybersecurity risk and find issues
1438 before an external party does. Comprised of Product Security members and other
1439 participants (such as 3rd parties) as needed.

1440
1441 Larger organizations may choose to have multiple business or product-specific roles
1442 including a dedicated product security officer, manager, and/or engineers.
1443

1444 **Healthcare Provider**

- 1445 ● Healthcare providers may create similar organizational structures to align with vendors
1446 under a Chief Clinical Information Security/Cybersecurity Officer, with distinct
1447 consideration for the healthcare provider’s specific needs relating to security during the
1448 procurement, operation, and decommissioning of medical devices and health IT products.
- 1449 ● A broad set of stakeholders should be involved including people from clinical practices,
1450 medical device support organizations and technology and security areas.

1451

1452 **Appendix I: Example Organizational Training**

1453 The intent of this appendix section is to provide training information that will help organizations
1454 mature their cybersecurity programs. A comprehensive training program for cybersecurity
1455 includes the following:

1456

- 1457 ● **Training Requirements**

1458 Requirements for training each relevant role must be established and periodically
1459 reviewed to determine if they need to be updated.

- 1460 ● **General Awareness Training**

1461 All relevant employees in the organization should understand the principles of
1462 cybersecurity, the framework of the organization's program and the different roles and
1463 responsibilities for cybersecurity.

- 1464 ● **Training by Roles**

- 1465 ○ Training for Security Practitioners

- 1466 ■ Engineers

- 1467 ● Architecture: Security experts who participate in architecting
1468 products or contribute to the security architecture components of
1469 products should be trained in secure architecture principles and
1470 patterns.

- 1471 ● Threat modeling and security risk analysis: Security experts who
1472 participate in threat modeling should be trained in the principles of
1473 threat modeling and the use of threat modeling tools, as well as
1474 methods of translating threats into a risk management framework.

- 1475 ● Design: Security experts who participate in product design or
1476 contribute to the security design of products should be trained in
1477 secure design principles and patterns.

- 1478 ● Testing: Security experts who perform or guide security testing of
1479 products should be trained in security testing methodologies, tools
1480 and interpretation of testing results.

- 1481 ● Forensics and Incident Response: Security experts who evaluate
1482 evidence of security incidents should have training in security
1483 forensic analysis in addition to practical experience. Those who
1484 participate in the incident response process should be trained in
1485 that process and the theory of incident response, in addition to
1486 practical experience.

- 1487 ■ Penetration Testing: Penetration testers should have proper training in
1488 penetration testing techniques and tools as well as considerable practical
1489 experience before being qualified as a penetration tester for products.

- 1490 ■ Security Officers/Directors/Managers/Advocates/Champions: Non-
1491 technical security practitioners should be trained in the secure
1492 development lifecycle, the company's security framework and the
1493 company's quality system.

- 1494 ○ Training for Related Activities – Non-dedicated Practitioners

- 1495 ■ Software/firmware/hardware/systems engineers

- 1496 ● Secure Coding standards: Engineers involved in developing code
- 1497 should be trained in secure coding standards.
- 1498 ● Static and dynamic code analysis tools: Engineers involved in
- 1499 development and/or configuration management should be trained
- 1500 in the use and interpretation of automated code analysis tools.
- 1501 ▪ Sustaining engineering (maintenance for vulnerabilities): Engineers and
- 1502 product managers involved in maintenance of commercialized products
- 1503 should be trained in the interpretation of vulnerability notifications and the
- 1504 steps necessary to respond to vulnerabilities identified in the products.
- 1505 ▪ Risk managers: Risk managers should be trained on the incorporation and
- 1506 interpretation of security risks within the existing risk management
- 1507 framework.
- 1508 ▪ Requirements engineers: Requirements engineers should be trained to be
- 1509 able to incorporate standard security requirements into risk catalogs as
- 1510 well as novel requirements identified during threat modeling.
- 1511 ▪ Deployment engineers: Those responsible for deploying products in the
- 1512 field should be trained on adapting the products to the IT environment as
- 1513 well as configuring that environment, to match the security requirements
- 1514 specified for the products.
- 1515 ▪ Support and service engineers: Support and service engineers should be
- 1516 trained to recognize, remediate and escalate security issues reported or
- 1517 discovered in fielded systems.
- 1518 ▪ Information Security/IT/Systems Administration (infrastructure): Those
- 1519 responsible for defining and implementing the security infrastructure of
- 1520 the company's IT and physical environments should be trained in the
- 1521 access and protection requirements of secure development and
- 1522 manufacturing.
- 1523 ● **Periodic refreshers for awareness:** Employees who have participated in the overall
- 1524 awareness and more detailed training should be given periodic refresher training to
- 1525 remind them of the key elements of the previously acquired training.
- 1526 ● **Periodic updates for changes in threat landscape, technology, program:** As the threat
- 1527 landscape changes, as new technology is developed in cybersecurity and as the
- 1528 company's security program evolves, the training requirements and trainings themselves
- 1529 should be updated to stay in synchronization.
- 1530 ● **Qualification and Certification of Security Experts:**
- 1531 ○ Certification: Requirements for certification for security experts and practitioners
- 1532 should be established and upheld as minimum qualifications to participate in these
- 1533 activities. Certifications can be external and/or internal (based on completion and
- 1534 confirmation of an internal training regime).
- 1535 ○ On the job experience: Minimum requirements for actual experience practicing
- 1536 security activities should be specified for a person to be considered a security
- 1537 expert in a particular sub-role of expertise.
- 1538 ○ Mentoring and community: Participation in the community of experts within the
- 1539 company should be included as a requirement to be considered a security expert.
- 1540 This may include peer relationships as well as mentor-mentee relationships.

- 1541 ○ Levels of expertise: Different levels of expertise should be defined by the degree
1542 to which a practitioner has achieved these aspects of qualification. The levels
1543 should correspond to minimum requirements for specific security-related
1544 activities. For instance, a penetration tester may be allowed to be the lead tester
1545 for a product only in the case of a minimum amount of time practicing as a
1546 penetration tester.
- 1547 ● **Drills:** Periodic drills should be exercised, in order to ensure the ability of practitioners to
1548 apply trainings. These may take the form of tabletop incident response drills or full-
1549 blown red team/blue team exercises.

1550

1551 **Appendix J: Example Security Risk Assessment Methods**

1552 **Common Vulnerability Scoring System Rubric for Healthcare**

1553 CVSS provides a way to characterize and assess the severity of a cybersecurity vulnerability, and
1554 the IT industry has used it effectively to manage system and software vulnerabilities for many
1555 years. The purpose of this appendix section is to provide additional healthcare context for end
1556 users and vendors that leverage CVSS as a part of their vulnerability assessment.

1557 CVSS and its associated rubric and examples were developed for enterprise information
1558 technology systems and do not adequately reflect the clinical environment and potential patient
1559 safety impacts. As such, a CVSS supplemental rubric tailored to explicitly consider the clinical
1560 environment and potential impacts to patient safety is being developed in collaboration with
1561 subject matter experts across the medical device ecosystem. The intent is to use the rubric with
1562 CVSS to provide a consistent and standardized way to communicate the severity of a
1563 vulnerability between multiple parties, including the medical device manufacturer, hospitals,
1564 clinicians, patients, Department of Homeland Security (DHS), and vulnerability researchers.

1565 The draft “Rubric for Applying CVSS to Medical Devices” is found at
1566 <https://www.mitre.org/md-cvss-rubric>.

1567

1568 **Appendix K: CMMI® for Development**

1569 CMMI for development is a reference model that includes activities and best practices for
1570 developing products and services. There are 5 CMMI maturity levels from level 1 to level 5 and
1571 these maturity levels provide a means for organizations to assess and describe their performance.
1572 This appendix section provides an overview of these maturity levels which may also be found at
1573 <https://cmmiinstitute.com/learning/appraisals/levels>.

1574

1575 **Maturity Level 1: Initial**

1576 At maturity level 1, processes are usually ad hoc and chaotic. The organization usually does not
1577 provide a stable environment to support processes. Success in these organizations depends on the
1578 competence and heroics of the people in the organization and not on the use of proven processes.
1579 In spite of this chaos, maturity level 1 organizations often produce products and services that
1580 work, but they frequently exceed the budget and schedule documented in their plans. Maturity
1581 level 1 organizations are characterized by a tendency to overcommit, abandon their processes in

1582 a time of crisis, and be unable to repeat their successes.

1583

1584 **Maturity Level 2: Managed**

1585 At maturity level 2, the projects have ensured that processes are planned and executed in
1586 accordance with policy; the projects employ skilled people who have adequate resources to
1587 produce controlled outputs; involve relevant stakeholders; are monitored, controlled, and
1588 reviewed; and are evaluated for adherence to their process descriptions. The process discipline
1589 reflected by maturity level 2 helps to ensure that existing practices are retained during times of
1590 stress. When these practices are in place, projects are performed and managed according to their
1591 documented plans.

1592 Also at maturity level 2, the status of the work products are visible to management at defined
1593 points (e.g., at major milestones, at the completion of major tasks). Commitments are established
1594 among relevant stakeholders and are revised as needed. Work products are appropriately
1595 controlled. The work products and services satisfy their specified process descriptions, standards,
1596 and procedures.

1597

1598 **Maturity Level 3: Defined**

1599 At maturity level 3, processes are well characterized and understood, and are described in
1600 standards, procedures, tools, and methods. The organization's set of standard processes, which is
1601 the basis for maturity level 3, is established and improved over time. These standard processes
1602 are used to establish consistency across the organization. Projects establish their defined
1603 processes by tailoring the organization's set of standard processes according to tailoring
1604 guidelines. (See the definition of "organization's set of standard processes" in the glossary.)
1605

1606 A critical distinction between maturity levels 2 and 3 is the scope of standards, process
1607 descriptions, and procedures. At maturity level 2, the standards, process descriptions, and
1608 procedures can be quite different in each specific instance of the process (e.g., on a particular
1609 project). At maturity level 3, the standards, process descriptions, and procedures for a project are
1610 tailored from the organization's set of standard processes to suit a particular project or
1611 organizational unit and therefore are more consistent except for the differences allowed by the
1612 tailoring guidelines.

1613

1614 Another critical distinction is that at maturity level 3, processes are typically described more
1615 rigorously than at maturity level 2. A defined process clearly states the purpose, inputs, entry
1616 criteria, activities, roles, measures, verification steps, outputs, and exit criteria. At maturity level
1617 3, processes are managed more proactively using an understanding of the interrelationships of
1618 process activities and detailed measures of the process, its work products, and its services.
1619 At maturity level 3, the organization further improves its processes that are related to the
1620 maturity level 2 process areas. Generic practices associated with generic goal 3 that were not
1621 addressed at maturity level 2 are applied to achieve maturity level 3.

1622

1623 **Maturity Level 4: Quantitatively Managed**

1624 At maturity level 4, the organization and projects establish quantitative objectives for quality and
1625 process performance and use them as criteria in managing projects. Quantitative objectives are
1626 based on the needs of the customer, end users, organization, and process implementers. Quality

1627 and process performance is understood in statistical terms and is managed throughout the life of
1628 projects.

1629
1630 For selected subprocesses, specific measures of process performance are collected and
1631 statistically analyzed. When selecting subprocesses for analyses, it is critical to understand the
1632 relationships between different subprocesses and their impact on achieving the objectives for
1633 quality and process performance. Such an approach helps to ensure that subprocess monitoring
1634 using statistical and other quantitative techniques is applied to where it has the most overall
1635 value to the business. Process performance baselines and models can be used to help set quality
1636 and process performance objectives that help achieve business objectives.

1637
1638 A critical distinction between maturity levels 3 and 4 is the predictability of process
1639 performance. At maturity level 4, the performance of projects and selected subprocesses is
1640 controlled using statistical and other quantitative techniques, and predictions are based, in part,
1641 on a statistical analysis of fine-grained process data.

1642
1643 **Maturity Level 5: Optimizing**

1644 At maturity level 5, an organization continually improves its processes based on a quantitative
1645 understanding of its business objectives and performance needs. The organization uses a
1646 quantitative approach to understand the variation inherent in the process and the causes of
1647 process outcomes.

1648
1649 Maturity level 5 focuses on continually improving process performance through incremental and
1650 innovative process and technological improvements. The organization's quality and process
1651 performance objectives are established, continually revised to reflect changing business
1652 objectives and organizational performance, and used as criteria in managing process
1653 improvement. The effects of deployed process improvements are measured using statistical and
1654 other quantitative techniques and compared to quality and process performance objectives. The
1655 project's defined processes, the organization's set of standard processes, and supporting
1656 technology are targets of measurable improvement activities.

1657
1658 A critical distinction between maturity levels 4 and 5 is the focus on managing and improving
1659 organizational performance. At maturity level 4, the organization and projects focus on
1660 understanding and controlling performance at the subprocess level and using the results to
1661 manage projects. At maturity level 5, the organization is concerned with overall organizational
1662 performance using data collected from multiple projects. Analysis of the data identifies shortfalls
1663 or gaps in performance. These gaps are used to drive organizational process improvement that
1664 generates measurable improvement in performance.

1665
1666 ##